



PCT/GB 2004 / 0 0 2 6 2 .1



INVESTOR IN PEOPLE

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

REC'D 0 6 JUL 2004

WIPO

PCT

PRIORITY DOCUMENT

SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

Signed

Dated

Andrew Gersey
30 June 2004



23JUN03 EB16819-3 C72481
P01/7700 0:00-0314492.0

1/77

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

The Patent Office

Cardiff Road
Newport
South Wales
NP10 8QQ

1. Your reference

PA 532

2. Patent application number

(The Patent Office will fill in this part)

0314492.0

3. Full name, address and postcode of the or of each applicant (underline all surnames)

CELLTECH R&D LIMITED
208 BATH ROAD

Patents ADP number (if you know it)

SLOUGH, SL1 3WE

If the applicant is a corporate body, give the country/state of its incorporation

UK

BERKSHIRE

8121685001

4. Title of the invention

5. Name of your agent (if you have one)

"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)

CELLTECH R&D LIMITED
PATENTS DEPARTMENT
208 BATH ROAD
SLOUGH, SL1 3WE
BERKSHIRE

Patents ADP number (if you know it)

8182305001

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number

Country

Priority application number
(if you know it)

Date of filing
(day / month / year)

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application

Date of filing
(day / month / year)

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if:

a) any applicant named in part 3 is not an inventor, or
b) there is an inventor who is not named as an applicant, or

c) any named applicant is a corporate body.

See note (d))

Yes

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form

Description

Claim(s)

Abstract

Drawing(s)

0
96

0

0

0

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (Patents Form 7/77)

Request for preliminary examination and search (Patents Form 9/77)

Request for substantive examination (Patents Form 10/77)

Any other documents (please specify)

0

0

0

0

0

0

11. I/We request the grant of a patent on the basis of this application. For and on Behalf of CELLTECH RESEARCH LTD.

Signature

Date

[Signature]

20/6/03

12. Name and daytime telephone number of person to contact in the United Kingdom

DR. PHILLIP ANSELL 01753 534655

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 08459 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- For details of the fee and ways to pay please contact the Patent Office.

CHEMICAL COMPOUNDS

5 This invention relates to a series of thienopyridone derivatives, to compositions containing them, to processes for their preparation and to their use in medicine.

10 Immune and inflammatory responses involve a variety of cell types with control and co-ordination of the various interactions occurring *via* both cell-cell contacts (e.g integrin interactions with their receptors) and by way of intercellular signalling molecules. A large number of different signalling molecules are involved, including cytokines, lymphocytes, chemokines and growth factors.

15 Cells respond to such intercellular signalling molecules by means of intracellular signalling mechanisms that include protein kinases, phosphatases and phospholipases. There are five classes of protein kinase of which the major ones are the tyrosine kinases and the serine/threonine kinases [Hunter, T., Methods in Enzymology (Protein Kinase Classification)
20 p. 3, Hunter, T. and Sefton, B.M.; eds. Vol. 200, Academic Press; San Diego, 1991].

25 One sub-class of serine/threonine kinases is the mitogen activating protein (MAP) kinases of which there are at least three families which differ in the sequence and size of the activation loop [Adams, J. L. *et al*, Progress in Medicinal Chemistry p. 1-60, King, F. D. and Oxford, A. W.; eds. vol 38, Elsevier Science, 2001]: (i) the extracellular regulated kinases (ERKs), (ii) the c-Jun NH₂ terminal kinases or stress activated kinases (JNKs or SAP kinases) and (iii) the p38 kinases which have a threonine-glycine-tyrosine
30 (TGY) activation motif. Both the JNKs and p38 MAP kinases are primarily activated by stress stimuli including, but not limited to, proinflammatory cytokines e.g. tumour necrosis factor (TNF) and interleukin-1 (IL-1), ultraviolet light, endotoxin and chemical or osmotic shock.

Four isoforms of p38 have been described (p38 α /p38 β /p38 γ /p38 δ). The human p38 α enzyme was initially identified as a target of cytokine-suppressive anti-inflammatory drugs (CSAIDs) and the two isoenzymes found were initially
5 termed CSAID binding protein-1 (CSBP-1) and CSBP-2. [Lee, J. C. *et al*, Nature (London) 1994, 372, 739-46]. CSBP-2 is now widely referred to as p38 α and differs from CSBP-1 in an internal sequence of 25 amino acids as a result of differential splicing of two exons that are conserved in both mouse and human [McDonnell, P. C. *et al*, Genomics 1995, 29, 301-2]. CSBP-1 and
10 p38 α are expressed ubiquitously and there is no difference between the two isoforms with respect to tissue distribution, activation profile, substrate preference or CSAID binding. A second isoform is p38 β which has 70% identity with p38 α . A second form of p38 β termed p38 β 2 is also known and of the two this is believed to be the major form. p38 α and p38 β 2 are expressed
15 in many different tissues. However in monocytes and macrophages p38 α is the predominant kinase activity [Lee, J. C., *ibid*; Jing, Y. *et al*, J. Biol. Chem. 1996, 271, 10531-34; Hale, K. K. *et al*, J. Immun. 1999, 162, 4246-52]. p38 γ and p38 δ (also termed SAP kinase-3 and SAP kinase-4 respectively) have ~63% and ~61% homology to p38 α respectively. p38 γ is predominantly
20 expressed in skeletal muscle whilst p38 δ is found in testes, pancreas, prostate, small intestine and in certain endocrine tissues.

All p38 homologues and splice variants contain a 12 amino acid activation loop that includes a Thr-Gly-Tyr motif. Dual phosphorylation of both Thr-180
25 and Tyr-182 in the TGY motif by a dual specificity upstream kinase is essential for the activation of p38 and results in a >1000-fold increase in specific activity of these enzymes [Doza, Y. N. *et al* FEBS Lett., 1995, 364, 7095-8012]. This dual phosphorylation is effected by MKK6 and under certain conditions the related enzyme MKK3 [Enslin, H. *et al* J. Biol. Chem., 1998,
30 273, 1741-48]. MKK3 and MKK6 belong to a family of enzymes termed

MAPKK (mitogen activating protein kinase kinase) which are in turn activated by MAPKKK (mitogen activating kinase kinase kinase) otherwise known as MAP3K.

- 5 Several MAP3Ks have been identified that are activated by a wide variety of stimuli including environmental stress, inflammatory cytokines and other factors. MEKK4/MTK1 (MAP or ERK kinase kinase/MAP three kinase-1), ASK1 (apoptosis stimulated kinase) and TAK1 (TGF- β -activated kinase) are some of the enzymes identified as upstream activators of for MAPKKs.
- 10 MEKK4/MTK1 is thought to be activated by several GADD-45-like genes that are induced in response to environmental stimuli and which eventually lead to p38 activation [Takekawa, M. and Saito, H. Cell, 1998, 95, 521-30]. TAK1 has been shown to activate MKK6 in response to transforming growth factor- β (TGF- β). TNF-stimulated activation of p38 is believed to be mediated by the
- 15 recruitment of TRAF2 [TNF receptor associated factor] and the Fas adaptor protein, Daxx, which results in the activation of ASK1 and subsequently p38.

- Several substrates of p38 have been identified including other kinases [e.g. MAPK activated protein kinase 2/3/5 (MAPKAP 2/3/5), p38
- 20 regulated/activated protein kinase (PRAK), MAP kinase-interacting kinase 1/2 (MNK1/2), mitogen- and stress-activated protein kinase 1 (MSK1/RLPK) and ribosomal S6 kinase-B (RSK-B)]; transcription factors [e.g. activating transcription factor 2/6 (ATF2/6), monocyte-enhancer factor-2A/C (MEF2A/C), C/EBP homologous protein (CHOP), Elk1 and Sap-1a1]; and
- 25 other substrates [e.g. cPLA2, p47phox].

- MAPKAP K2 is activated by p38 in response to environmental stress. Mice engineered to lack MAPKAP K2 do not produce TNF in response to lipopolysaccharide (LPS). Production of several other cytokines such as IL-1,
- 30 IL-6, IFN- γ and IL-10 is also partially inhibited [Kotlyarov, A. *et al* Nature Cell Biol. 1999, 1, 94-7]. Further, MAPKAP K2 from embryonic stem cells from

p38 α null mice was not activated in response to stress and these cells did not produce IL-6 in response to IL-1 [Allen, M. *et al*, J. Exp. Med. 2000, 191, 859-69]. These results indicate that MAPKAP K2 is not only essential for TNF and IL-1 production but also for signalling induced by cytokines. In addition
5 MAPKAP K2/3 phosphorylate and thus regulate heat shock proteins HSP 25 and HSP 27 which are involved in cytoskeletal reorganization.

Several small molecule inhibitors of p38 have been reported which inhibit IL-1 and TNF synthesis in human monocytes at concentrations in the low μ M
10 range [Lee, J. C. *et al*, Int. J. Immunopharm. 1988, 10, 835] and exhibit activity in animal models which are refractory to cyclooxygenase inhibitors [Lee, J. C. *et al*, Annals N. Y. Acad. Sci. 1993, 696, 149]. In addition these small molecule inhibitors are known to decrease the synthesis of a wide variety of pro-inflammatory proteins including IL-6, IL-8,
15 granulocyte/macrophage colony-stimulating factor (GM-CSF) and cyclooxygenase-2 (COX-2). TNF-induced phosphorylation and activation of cytosolic PLA2, TNF-induced expression of VCAM-1 on endothelial cells and IL-1 stimulated synthesis of collagenase and stromelysin are also inhibited by small molecule inhibitors of p38 [Cohen, P. Trends Cell Biol. 1997, 7, 353-
20 61].

A variety of cells including monocytes and macrophages produce TNF and IL-1. Excessive or unregulated TNF production is implicated in a number of disease states including Crohn's disease, ulcerative colitis, pyresis,
25 rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis and other arthritic conditions, toxic shock syndrome, endotoxic shock, sepsis, septic shock, gram negative sepsis, bone resorption diseases, reperfusion injury, graft vs. host reaction, allograft rejection, adult respiratory distress syndrome, chronic pulmonary inflammatory disease, silicosis, pulmonary
30 sarcoisosis, cerebral malaria, scar tissue formation, keloid formation, fever and myalgias due to infection, such as influenza, cachexia secondary to

acquired immune deficiency syndrome (AIDS), cachexia secondary to infection or malignancy, AIDS or AIDS related complex.

5 Excessive or unregulated IL-1 production has been implicated in rheumatoid arthritis, osteoarthritis, traumatic arthritis, rubella arthritis, acute synovitis, psoriatic arthritis, cachexia, Reiter's syndrome, endotoxemia, toxic shock syndrome, tuberculosis, atherosclerosis, muscle degeneration, and other acute or chronic inflammatory diseases such as the inflammatory reaction induced by endotoxin or inflammatory bowel disease. In addition IL-1 has
10 been linked to diabetes and pancreatic β cells [Dinarello, C. A. J. Clinical Immunology, 1985, 5, 287-97].

IL-8 is a chemotactic factor produced by various cell types including endothelial cells, mononuclear cells, fibroblasts and keratinocytes. IL-1, TNF
15 and LPS all induce the production of IL-8 by endothelial cells. *In vitro* IL-8 has been shown to have a number of functions including being a chemoattractant for neutrophils, T-lymphocytes and basophils. IL-8 has also been shown to increase the surface expression of Mac-1 (CD11b/CD18) on neutrophils without *de novo* protein synthesis which may contribute to increased
20 adhesion of neutrophils to vascular endothelial cells. Many diseases are characterised by massive neutrophil infiltration. Histamine release from basophils (in both atopic and normal individuals) is induced by IL-8 as is lysozomal enzyme release and respiratory burst from neutrophils.


25 The central role of IL-1 and TNF together with other leukocyte derived cytokines as important and critical inflammatory mediators is well documented. The inhibition of these cytokines has been shown or would be expected to be of benefit in controlling, alleviating or reducing many of these disease states.

30

The central position that p38 occupies within the cascade of signalling molecules mediating extracellular to intracellular signalling and its influence over not only IL-1, TNF and IL-8 production but also the synthesis and/or action of other pro-inflammatory proteins (e.g. IL-6, GM-CSF, COX-2, collagenase and stromelysin) make it an attractive target for inhibition by small molecule inhibitors with the expectation that such inhibition would be a highly effective mechanism for regulating the excessive and destructive activation of the immune system. Such an expectation is supported by the potent and diverse anti-inflammatory activities described for p38 kinase inhibitors [Adams, *ibid*; Badger, *et al*, J. Pharm. Exp. Ther. 1996, 279, 1453-61; Griswold, *et al*, Pharmacol. Comm., 1996, 7, 323-29].

We have now found a group of compounds which are potent and selective inhibitors of p38 kinase (p38 α , β , δ and γ) and the isoforms and splice variants thereof, especially p38 α , p38 β and p38 β 2. The compounds are thus of use in medicine, for example in the prophylaxis and treatment of immune or inflammatory disorders as described herein.

Thus according to one aspect of the invention we provide a compound of formula (1) :



wherein:

Y is a linking group $-\text{C}(\text{O})-$ or $-\text{S}(\text{O}_2)-$;

n is zero or the integer 1;

m is the integer 1, 2, 3 or 4;

p is the integer 1, 2, 3 or 4;

5 R^d is an $-\text{OH}$, $-(\text{Alk}^2)\text{OH}$ (where Alk^2 is a straight or branched C_{1-4} alkylene chain), $-\text{OR}^1$ (where R^1 is a straight or branched C_{1-6} alkyl group), $-(\text{Alk}^2)\text{OR}^1$, $-\text{NR}^2\text{R}^3$ (where R^2 and R^3 may be the same or different and is each independently a hydrogen atom or straight or branched C_{1-6} alkyl group), $-(\text{Alk}^2)\text{NR}^2\text{R}^3$ or straight or branched C_{1-6} alkyl group;

10 Alk^1 is a straight or branched C_{1-4} alkylene chain;

Cy^1 is an optionally substituted cycloaliphatic, aromatic or heteroaromatic group;

Ar is an optionally substituted aromatic or heteroaromatic group;

and the salts, solvates, hydrates and N-oxides thereof.

15

It will be appreciated that compounds of formula (1) may have one or more chiral centres, and exist as enantiomers or diastereomers. The invention is to be understood to extend to all such enantiomers, diastereomers and mixtures thereof, including racemates. Formula (1) and the formulae hereinafter are intended to represent all individual isomers and mixtures thereof, unless stated or shown otherwise. In addition, compounds of formula (1) may exist as tautomers, for example keto ($\text{CH}_2\text{C}=\text{O}$)-enol ($\text{CH}=\text{CHOH}$) tautomers. Formula (1) and the formulae hereinafter are intended to represent all individual tautomers and mixtures thereof, unless stated otherwise.

25

The following general terms as used herein in relation to compounds of the invention and intermediates thereto have the stated meaning below unless specifically defined otherwise.

30

- Thus as used herein the term "alkyl" whether present as a group or part of a group includes straight or branched C₁₋₆alkyl groups, for example C₁₋₄alkyl groups such as methyl, ethyl, n-propyl, i-propyl, n-butyl, s-butyl, i-butyl or t-butyl groups. Similarly, the terms "alkenyl" or "alkynyl" are intended to mean
- 5 straight or branched C₂₋₆alkenyl or C₂₋₆alkynyl groups such as C₂₋₄alkenyl or C₂₋₄alkynyl groups. The optional substituents which may be present on these groups include one, two, three or more substituents where each substituent may be the same or different and is selected from halogen atoms, e.g. fluorine, chlorine, bromine or iodine atoms, or -OH, -CO₂H, -CO₂R⁴ [where R⁴ is an
- 10 optionally substituted straight or branched C₁₋₆alkyl group, and is in particular a straight or branched C₁₋₄alkyl group], e.g. -CO₂CH₃ or -CO₂C(CH₃)₃, -CONHR⁴, e.g. -CONHCH₃, -CON(R⁴)₂, e.g. -CON(CH₃)₂, -COR⁴, e.g. -COCH₃, C₁₋₆alkoxy, e.g. methoxy or ethoxy, haloC₁₋₆alkoxy, e.g. trifluoromethoxy or difluoromethoxy, thiol (-SH), -S(O)R⁴, e.g. -S(O)CH₃, -
- 15 S(O)₂R⁴, e.g. -S(O)₂CH₃, C₁₋₆alkylthio e.g. methylthio or ethylthio, amino, -NHR⁴, e.g. -NHCH₃ or -N(R⁴)₂, e.g. -N(CH₃)₂ groups. Where two R⁴ groups are present in any of the above substituents these may be the same or different.
- 20 In addition when two R⁴ alkyl groups are present in any of the optional substituents just described these groups may be joined, together with the N atom to which they are attached, to form a heterocyclic ring. Such heterocyclic rings may be optionally interrupted by a further heteroatom or heteroatom containing group selected from -O-, -S-, -N(R⁴)-, -C(O)- or -
- 25 C(S)- groups. Particular examples of such heterocyclic rings include piperidinyl, pyrazolidinyl, morpholinyl, thiomorpholinyl, pyrrolidinyl, imidazolidinyl and piperazinyl rings.

The term halogen is intended to include fluorine, chlorine, bromine or iodine

30 atoms.

The term "haloalkyl" is intended to include those alkyl groups just mentioned substituted by one, two or three of the halogen atoms just described. Particular examples of such groups include $-\text{CF}_3$, $-\text{CCl}_3$, $-\text{CHF}_2$, $-\text{CHCl}_2$, $-\text{CH}_2\text{F}$ and $-\text{CH}_2\text{Cl}$ groups.

5

The term "alkoxy" as used herein is intended to include straight or branched C_{1-6} alkoxy e.g. C_{1-4} alkoxy such as methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, s-butoxy, i-butoxy and t-butoxy. "Haloalkoxy" as used herein includes any of these alkoxy groups substituted by one, two or three halogen atoms as described above. Particular examples include $-\text{OCF}_3$, $-\text{OCCl}_3$, $-\text{OCHF}_2$, $-\text{OCHCl}_2$, $-\text{OCH}_2\text{F}$ and $-\text{OCH}_2\text{Cl}$ groups.

10

As used herein the term "alkylthio" is intended to include straight or branched C_{1-6} alkylthio, e.g. C_{1-4} alkylthio such as methylthio or ethylthio.

15

As used herein the term "alkylamino or dialkylamino" is intended to include the groups $-\text{NHR}^{1a}$ and $-\text{N}(\text{R}^{1a})(\text{R}^{1b})$ where R^{1a} and R^{1b} is each independently an optionally substituted straight or branched alkyl group or both together with the N atom to which they are attached form an optionally substituted heterocycloalkyl group which may contain a further heteroatom or heteroatom containing group such as an $-\text{O}-$ or $-\text{S}-$ atom or $-\text{N}(\text{R}^{1a})-$ group. Particular examples of such optionally substituted heterocycloalkyl groups include optionally substituted pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl and $\text{N}'\text{-C}_{1-6}$ alkyl-piperazinyl groups. The optional substituents which may be present on such heterocycloalkyl groups include those optional substituents as described above in relation to the term "alkyl".

20

25

Particular examples of alkylene chains represented by Alk^1 and/or Alk^2 when each is present in compounds of the invention include $-\text{CH}_2-$, $-\text{CH}_2\text{CH}_2-$, $-\text{CH}(\text{CH}_3)\text{CH}_2-$, $-(\text{CH}_2)_2\text{CH}_2-$, $-\text{C}(\text{CH}_3)_2-$, $-(\text{CH}_2)_3\text{CH}_2-$, $-\text{CH}_2\text{CH}(\text{CH}_3)\text{CH}_2-$, $-\text{C}(\text{CH}_3)_2\text{CH}_2-$ or $-\text{CH}(\text{CH}_3)\text{CH}_2\text{CH}_2-$ chains.

30

Optionally substituted cycloaliphatic groups represented by the group Cy¹ in
5 compounds of the invention include optionally substituted C₃₋₁₀cycloaliphatic
groups. Particular examples include optionally substituted C₃₋₁₀cycloalkyl, e.g.
C₃₋₇cycloalkyl or C₃₋₁₀cycloalkenyl, e.g. C₃₋₇cycloalkenyl groups.

Particular examples of cycloaliphatic groups represented by the group Cy¹
10 include optionally substituted cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,
cycloheptyl, 2-cyclobuten-1-yl, 2-cyclopenten-1-yl, or 3-cyclopenten-1-yl,
groups.

The optional substituents which may be present on the cycloaliphatic, groups
15 represented by the group Cy¹ include one, two, three or more substituents
selected from halogen atoms, or C₁₋₆alkyl, e.g. methyl or ethyl, haloC₁₋₆alkyl,
e.g. halomethyl or haloethyl such as difluoromethyl or trifluoromethyl,
optionally substituted by hydroxyl, e.g. -C(OH)(CF₃)₂, C₁₋₆alkoxy, e.g.
methoxy or ethoxy, haloC₁₋₆alkoxy, eg. halomethoxy or haloethoxy such as
20 difluoromethoxy or trifluoromethoxy, thiol, C₁₋₆alkylthiol, e.g. methylthiol or
ethylthiol, carbonyl (=O), thiocarbonyl (=S), imino (=NR^{4a}) [where R^{4a} is an -
OH group or a C₁₋₆alkyl group], or -(Alk³)_vR⁵ groups in which Alk³ is a straight
or branched C₁₋₃alkylene chain, v is zero or the integer 1 and R⁵ is a C<sub>3-
8</sub>cycloalkyl, -OH, -SH, -N(R⁶)(R⁷) [in which R⁶ and R⁷ is each independently
25 selected from a hydrogen atom or an optionally substituted alkyl or C<sub>3-
8</sub>cycloalkyl group], -OR⁶, -SR⁶, -CN, -NO₂, -CO₂R⁶, -SOR⁶, -SO₂R⁶, -SO₃R⁶, -
OCO₂R⁶, -C(O)R⁶, -OC(O)R⁶, -C(S)R⁶, -C(O)N(R⁶)(R⁷), -OC(O)N(R⁶)(R⁷), -
N(R⁶)C(O)R⁷, -C(S)N(R⁶)(R⁷), -N(R⁶)C(S)R⁷, -SO₂N(R⁶)(R⁷), -N(R⁶)SO₂R⁷, -
N(R⁶)C(O)N(R⁷)(R⁸) [where R⁸ is as defined for R⁶], -N(R⁶)C(S)N(R⁷)(R⁸), -
30 N(R⁶)SO₂N(R⁷)(R⁸) or an optionally substituted aromatic or heteroaromatic
group.

Particular examples of Alk^3 chains include $-\text{CH}_2-$, $-\text{CH}_2\text{CH}_2-$, $-\text{CH}_2\text{CH}_2\text{CH}_2-$ and $-\text{CH}(\text{CH}_3)\text{CH}_2-$ chains.

- 5 When R^5 , R^6 , R^7 and/or R^8 is present as a C_{3-8} cycloalkyl group it may be for example a cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl group. Optional substituents which may be present on such groups include for example one, two or three substituents which may be the same or different selected from halogen atoms, for example fluorine, chlorine, bromine or iodine atoms, or
- 10 hydroxy or C_{1-6} alkoxy, e.g. methoxy, ethoxy or *i*-propoxy groups.

- When the groups R^6 and R^7 or R^7 and R^8 are both alkyl groups these groups may be joined, together with the N atom to which they are attached, to form a heterocyclic ring. Such heterocyclic rings may be optionally interrupted by a
- 15 further heteroatom or heteroatom containing group selected from $-\text{O}-$, $-\text{S}-$, $-\text{N}(\text{R}^7)-$, $-\text{C}(\text{O})-$ or $-\text{C}(\text{S})-$ groups. Particular examples of such heterocyclic rings include piperidinyl, pyrazolidinyl, morpholinyl, thiomorpholinyl, pyrrolidinyl, imidazolidinyl and piperazinyl rings.

- 20 When R^5 is an optionally substituted aromatic or heteroaromatic group it may be any such group as described hereinafter in relation to Cy^1 .
- 25 In general, optionally substituted aromatic groups represented by the group Cy^1 include for example monocyclic or bicyclic fused ring C_{6-12} aromatic groups, such as phenyl, 1- or 2-naphthyl, 1- or 2-tetrahydronaphthyl, indanyl or indenyl groups.
- 30 Heteroaromatic groups represented by the group Cy^1 include for example C_{1-9} heteroaromatic groups containing for example one, two, three or four

heteroatoms selected from oxygen, sulphur or nitrogen atoms. In general, the heteroaromatic groups may be for example monocyclic or bicyclic fused ring heteroaromatic groups. Monocyclic heteroaromatic groups include for example five- or six-membered heteroaromatic groups containing one, two, three or four heteroatoms selected from oxygen, sulphur or nitrogen atoms. Bicyclic heteroaromatic groups include for example eight- to thirteen-membered fused ring heteroaromatic groups containing one, two or more heteroatoms selected from oxygen, sulphur or nitrogen atoms.

- 10 Particular examples of heteroaromatic groups of these types include pyrrolyl, furyl, thienyl, imidazolyl, N-C₁₋₆alkylimidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,3-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, 1,3,4-thiadiazolyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, 1,3,5-triazinyl, 1,2,4-triazinyl, 1,2,3-triazinyl, benzofuryl, [2,3-dihydro]benzofuryl, benzothienyl, [2,3-dihydro]benzothienyl, benzotriazolyl, indolyl, indolynyl, indazolynyl, benzimidazolyl, imidazo[1,2-a]pyridyl, benzothiazolyl, benzoxazolyl, benzisoxazolyl, benzopyranyl, [3,4-dihydro]benzopyranyl, quinazolinyl, quinoxalinyl, naphthyridinyl, imidazo[1,5-a]pyridinyl, imidazo[1,5-a]pyrazinyl, imidazo[1,5-c]pyrimidinyl, pyrido[3,4-b]pyridyl, pyrido[3,2-b]pyridyl, pyrido[4,3-b]pyridyl, quinolynyl, isoquinolynyl, phthalazinyl, tetrazolyl, 5,6,7,8-tetrahydroquinolynyl, 5,6,7,8-tetrahydroisoquinolynyl, imidyl, e.g. succinimidyl, phthalimidyl or naphthalimidyl such as 1,8-naphthalimidyl, pyrazolo[4,3-d]pyrimidinyl, furo[3,2-d]pyrimidinyl, thieno[3,2-d]pyrimidinyl, pyrrolo[3,2-d]pyrimidinyl, pyrazolo[3,2-b]pyridinyl, furo[3,2-b]pyridinyl, thieno[3,2-b]pyridinyl, pyrrolo[3,2-b]pyridinyl, thiazolo[3,2-a]pyridinyl, pyrido[1,2-a]pyrimidinyl, tetrahydroimidazo[1,2-a]pyrimidinyl and dihydroimidazo[1,2-a]pyrimidinyl groups.
- 30 Optional substituents which may be present on aromatic or heteroaromatic groups represented by the group Cy¹ include one, two, three or more

substituents, each selected from an atom or group R^{10} in which R^{10} is R^{10a} or $-L^6Alk^5(R^{10a})_r$, where R^{10a} is a halogen atom, or an amino ($-NH_2$), substituted amino, nitro, cyano, hydroxyl ($-OH$), substituted hydroxyl, formyl, carboxyl ($-CO_2H$), esterified carboxyl, thiol ($-SH$), substituted thiol, $-COR^{11}$ [where R^{11} is an $-L^6Alk^3(R^{10a})_r$, aryl or heteroaryl group], $-CSR^{11}$, $-SO_3H$, $-SOR^{11}$, $-SO_2R^{11}$, $-SO_3R^{11}$, $-SO_2NH_2$, $-SO_2NHR^{11}$, $-SO_2N(R^{11})_2$, $-CONH_2$, $-CSNH_2$, $-CONHR^{11}$, $-CSNHR^{11}$, $-CON(R^{11})_2$, $-CSN(R^{11})_2$, $-N(R^{12})SO_2R^{11}$ [where R^{12} is a hydrogen atom or a straight or branched alkyl group], $-N(SO_2R^{11})_2$, $-N(R^{12})SO_2NH_2$, $-N(R^{12})SO_2NHR^{11}$, $-N(R^{12})SO_2N(R^{11})_2$, $-N(R^{12})COR^{11}$, $-N(R^{12})CONH_2$, $-N(R^{12})CONHR^{11}$, $-N(R^{12})CON(R^{11})_2$, $-N(R^{12})CSNH_2$, $-N(R^{12})CSNHR^{11}$, $-N(R^{12})CSN(R^{11})_2$, $-N(R^{12})CSR^{11}$, $-N(R^{12})C(O)OR^{11}$, $-C=NR^{12}(NR^{12})$, $-SO_2NHet^1$ [where $-NHet^1$ is an optionally substituted C_{3-7} cyclicamino group optionally containing one or more other $-O-$ or $-S-$ atoms or $-N(R^{12})-$, $-C(O)-$ or $-C(S)-$ groups], $-CONHet^1$, $-CSNHet^1$, $-N(R^{12})SO_2NHet^1$, $-N(R^{12})CONHet^1$, $-N(R^{12})CSNHet^1$, $-SO_2N(R^{12})Het$ [where $-Het$ is an optionally substituted monocyclic C_{3-7} carbocyclic group optionally containing one or more other $-O-$ or $-S-$ atoms or $-N(R^{12})-$, $-C(O)-$, $-S(O)-$ or $-S(O)_2-$ groups], $-Het$, $-CON(R^{12})Het$, $-CSN(R^{12})Het$, $-N(R^{12})CON(R^{12})Het$, $-N(R^{12})CSN(R^{12})Het$, $-N(R^{12})SO_2N(R^{12})Het$, aryl or heteroaryl groups; L^6 is a covalent bond or a linker atom or group; Alk^5 is an optionally substituted straight or branched C_1 -alkylene, C_{2-6} alkenylene or C_{2-6} alkynylene chain, optionally interrupted by one, two or three $-O-$ or $-S-$ atoms or $-S(O)_n-$ [where n is an integer 1 or 2] or $-N(R^{12})-$ e.g. $-N(CH_3)-$ groups; and r is zero or the integer 1, 2, or 3. It will be appreciated that when two R^{11} or R^{12} groups are present in one of the above substituents the R^{11} and R^{12} groups may be the same or different.

When L^6 in the group $-L^6Alk^5(R^{10a})_r$ is a linker atom or group it may be for example any divalent linking atom or group. Particular examples include $-O-$ or $-S-$ atoms or $-C(O)-$, $-C(O)O-$, $-OC(O)-$, $-C(S)-$, $-S(O)-$, $-S(O)_2-$, $-N(R^3)-$ [where R^3 is a hydrogen atom or a straight or branched alkyl group], $-N(R^3)O-$, $-N(R^3)N-$, $-CON(R^3)-$, $-OC(O)N(R^3)-$, $-CSN(R^3)-$, $-N(R^3)CO-$, $-N(R^3)C(O)O-$, $-$

$N(R^3)CS-$, $-S(O)_2N(R^3)-$, $-N(R^3)S(O)_2-$, $-N(R^3)CON(R^3)-$, $-N(R^3)CSN(R^3)-$ or $-N(R^3)SO_2N(R^3)-$ groups. Where L^6 contains two R^3 groups these may be the same or different.

- 5 When in the group $-L^6Alk^5(R^{10a})_r$, r is an integer 1, 2 or 3, it is to be understood that the substituent or substituents R^{10a} may be present on any suitable carbon atom in $-Alk^5$. Where more than one R^{10a} substituent is present these may be the same or different and may be present on the same or different atom in $-Alk^5$. Clearly, when r is zero and no substituent R^{10a} is present the alkylene, alkenylene or alkynylene chain represented by Alk^5 becomes an alkyl, alkenyl or alkynyl group.

- 15 When R^{10a} is a substituted amino group it may be for example a group $-NHR^{11}$ [where R^{11} is as defined above] or a group $-N(R^{11})_2$ wherein each R^{11} group is the same or different.

When R^{10a} is a halogen atom it may be for example a fluorine, chlorine, bromine, or iodine atom.

- 20 When R^{10a} is a substituted hydroxyl or substituted thiol group it may be for example a group $-OR^{11}$ or a $-SR^{12}$ group respectively.

- Esterified carboxyl groups represented by the group R^{10a} include groups of formula $-CO_2Alk^6$ wherein Alk^6 is a straight or branched, optionally substituted C_{1-8} alkyl group such as a methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl or t-butyl group; a C_{6-12} aryl C_{1-8} alkyl group such as an optionally substituted benzyl, phenylethyl, phenylpropyl, 1-naphthylmethyl or 2-naphthylmethyl group; a C_{6-12} aryl group such as an optionally substituted phenyl, 1-naphthyl or 2-naphthyl group; a C_{6-12} aryloxy C_{1-8} alkyl group such as an optionally substituted phenyloxymethyl, phenyloxyethyl, 1-naphthyloxymethyl, or 2-naphthyloxymethyl group; an optionally substituted C_{1-8} alkanoyloxy C_{1-8} alkyl group, such as a

pivaloyloxymethyl, propionyloxyethyl or propionyloxypropyl group; or a C₆₋₁₂aroxyloxyC₁₋₈alkyl group such as an optionally substituted benzoyloxyethyl or benzoyloxypropyl group. Optional substituents present on the Alk⁶ group include R^{10a} atoms and groups as described above.

5

When Alk⁵ is present in or as a substituent it may be for example a -CH₂-, -CH(CH₃)-, -C(CH₃)₂-, -CH₂CH₂-, -CH₂CH₂CH₂-, -CH(CH₃)CH₂-, -CH₂CH₂CH₂CH₂-, -CH₂CH(CH₃)CH₂-, -CH(CH₃)CH₂CH₂-, -C(CH₃)₂CH₂-, -CH=CH-, -CH=CCH₂-, -CH₂C=CH-, -CH=CHCH₂CH₂-, -CH₂CH=CHCH₂-, -CH₂CH₂CH=CH₂-, -CC-, -CCCH₂-, -CH₂CC-, -CCCH₂CH₂-, -CH₂CCCH₂- or -CH₂CH₂CC- chain, optionally interrupted by one, two, or three -O- or -S-, atoms or -S(O)-, -S(O)₂- or -N(R¹²)-, e.g. -N(CH₃)- groups. The aliphatic chains represented by Alk⁵ may be optionally substituted by one, two or three halogen atoms in addition to any R^{10a} groups that may be present.

15

Aryl or heteroaryl groups represented by the groups R^{10a} or R¹¹ include mono- or bicyclic optionally substituted C₆₋₁₂ aromatic or C₁₋₉ heteroaromatic groups as described above for the group Cy¹. The aromatic and heteroaromatic groups may be attached to the group Cy¹ in compounds of formula (1) by any carbon or hetero e.g. nitrogen atom as appropriate.

20

It will be appreciated that when -NHet¹ or -Het forms part of a substituent R¹⁰ the heteroatoms or heteroatom containing groups that may be present within the ring -NHet¹ or -Het take the place of carbon atoms within the parent carbocyclic ring.

25

Thus when -NHet¹ or -Het forms part of a substituent R¹⁰ each may be for example an optionally substituted pyrrolidinyl, imidazolidinyl, pyrazolidinyl, piperazinyl, morpholinyl, thiomorpholinyl, piperidinyl or thiazolidinyl group.

30

Additionally Het may represent for example, an optionally substituted cyclopentyl or cyclohexyl group. Optional substituents which may be present on

-NHet¹ include those substituents described above when Cy¹ is a heterocycloaliphatic group.

Particularly useful atoms or groups represented by R¹⁰ include fluorine, chlorine,
5 bromine or iodine atoms, or C₁₋₆alkyl, e.g. methyl, ethyl, n-propyl, i-propyl, n-butyl or t-butyl, optionally substituted phenyl, pyridyl, pyrimidinyl, pyrrolyl, furyl, thiazolyl, or thienyl, C₁₋₆hydroxyalkyl, e.g. hydroxymethyl or hydroxyethyl, carboxyC₁₋₆alkyl, e.g. carboxyethyl, C₁₋₆alkylthio e.g. methylthio or ethylthio, carboxyC₁₋₆alkylthio, e.g. carboxymethylthio, 2-carboxyethylthio or 3-carboxy-
10 propylthio, C₁₋₆alkoxy, e.g. methoxy or ethoxy, hydroxyC₁₋₆alkoxy, e.g. 2-hydroxyethoxy, optionally substituted phenoxy, pyridyloxy, thiazolyoxy, phenylthio or pyridylthio, C₃₋₇cycloalkyl, e.g. cyclobutyl, cyclopentyl, C₅₋₇cycloalkoxy, e.g. cyclopentyloxy, haloC₁₋₆alkyl, e.g. trifluoromethyl, haloC₁₋₆alkoxy, e.g. trifluoromethoxy, C₁₋₆alkylamino, e.g. methylamino, ethylamino, —
15 CH(CH₃)NH₂ or —C(CH₃)₂NH₂, haloC₁₋₆alkylamino, e.g. fluoroC₁₋₆alkylamino, e.g. —CH(CF₃)NH₂ or —C(CF₃)₂NH₂, amino (-NH₂), aminoC₁₋₆alkyl, e.g. aminomethyl or aminoethyl, C₁₋₆dialkylamino, e.g. dimethylamino or diethylamino, C₁₋₆alkylaminoC₁₋₆alkyl, e.g. ethylaminoethyl, C₁₋₆dialkylaminoC₁₋₆alkyl, e.g. diethylaminoethyl, aminoC₁₋₆alkoxy, e.g. aminoethoxy, C₁₋₆alkylaminoC₁₋₆alkoxy,
20 e.g. methylaminoethoxy, C₁₋₆dialkylaminoC₁₋₆alkoxy, e.g. dimethylaminoethoxy, diethylaminoethoxy, diisopropylaminoethoxy, or dimethylaminopropoxy, imido, such as phthalimido or naphthalimido, e.g. 1,8-naphthalimido, nitro, cyano, hydroxyl (-OH), formyl [HC(O)-], carboxyl (-CO₂H), -CO₂Alk⁶ [where Alk⁶ is as defined above], C₁₋₆alkanoyl e.g. acetyl, optionally substituted benzoyl, thiol (-
25 SH), thioC₁₋₆alkyl, e.g. thiomethyl or thioethyl, sulphonyl (-SO₃H), C₁₋₆alkylsulphonyl, e.g. methylsulphonyl, aminosulphonyl (-SO₂NH₂), C₁₋₆alkylaminosulphonyl, e.g. methylaminosulphonyl or ethylaminosulphonyl, C₁₋₆dialkylaminosulphonyl, e.g. dimethylaminosulphonyl or diethylaminosulphonyl, phenylaminosulphonyl, carboxamido (-CONH₂), C₁₋₆alkylaminocarbonyl, e.g.
30 methylaminocarbonyl or ethylaminocarbonyl, C₁₋₆dialkylaminocarbonyl, e.g. dimethylaminocarbonyl or diethylaminocarbonyl, aminoC₁₋₆alkylaminocarbonyl,

e.g. aminoethylamino-carbonyl, C₁₋₆dialkylaminoC₁₋₆alkylaminocarbonyl, e.g. diethylaminoethyl-aminocarbonyl, aminocarbonylamino, C₁₋₆alkylaminocarbonylamino, e.g. methylaminocarbonylamino or ethylaminocarbonylamino, C₁₋₆dialkylamino-carbonylamino, e.g. dimethylaminocarbonylamino or diethylamino-carbonylamino, C₁₋₆alkylaminocarbonylC₁₋₆alkylamino, e.g. methylamino-carbonylmethylamino, aminothiocabonylamino, C₁₋₆alkylaminothiocabonyl-amino, e.g. methylaminothiocabonylamino or ethylaminothiocabonylamino, C₁₋₆dialkylaminothiocabonylamino, e.g. dimethylaminothiocabonylamino or diethylaminothiocabonylamino, C₁₋₆alkylaminothiocabonylC₁₋₆alkylamino, e.g. ethylaminothiocabonylmethylamino, -CONHC(=NH)NH₂, C₁₋₆alkylsulphonylamino, e.g. methylsulphonylamino or ethylsulphonylamino, C₁₋₆dialkylsulphonylamino, e.g. dimethylsulphonylamino or diethylsulphonylamino, optionally substituted phenylsulphonylamino, aminosulphonylamino (-NHSO₂NH₂), C₁₋₆alkylaminosulphonylamino, e.g. methylaminosulphonylamino or ethylaminosulphonylamino, C₁₋₆dialkylaminosulphonylamino, e.g. dimethylaminosulphonylamino or diethylaminosulphonylamino, optionally substituted morpholinesulphonylamino or morpholinesulphonylC₁₋₆alkylamino, optionally substituted phenylaminosulphonylamino, C₁₋₆alkanoylamino, e.g. acetylamino, aminoC₁₋₆alkanoylamino e.g. aminoacetylamino, C₁₋₆dialkylaminoC₁₋₆alkanoylamino, e.g. dimethylaminoacetylamino, C₁₋₆alkanoylaminoC₁₋₆alkyl, e.g. acetylaminomethyl, C₁₋₆alkanoylaminoC₁₋₆alkylamino, e.g. acetamidoethylamino, C₁₋₆alkoxycarbonylamino, e.g. methoxycarbonylamino, ethoxycarbonylamino or t-butoxycarbonylamino or optionally substituted benzyloxy, pyridylmethoxy, thiazolylmethoxy, benzyloxycarbonylamino, benzyloxycarbonylaminoC₁₋₆alkyl e.g. benzyloxycarbonylaminoethyl, benzothio, pyridylmethylthio or thiazolylmethylthio groups.

A further particularly useful group of substituents represented by R¹⁰ when present on aromatic or heteroaromatic groups includes substituents of formula – L⁶Alk⁵R^{10a} where L⁶ is preferably a covalent bond or an –O- or –S- atom or –

N(R³)-, -C(O)-, -C(O)O-, -O-C(O)-, -N(R³)CO-, -CON(R³)- or -N(R³)S(O)₂- group, Alk⁵ is an optionally substituted C₁₋₆alkyl group optionally interrupted by one or two -O- or -S- atoms or -N(R¹²)-, -C(O)-, -C(S)-, -CON(R¹²)- or -N(R¹²)CO- groups and R^{10a} is an optionally substituted Het group as herein
5 defined or an optionally substituted heteroaromatic group as hereinbefore described in relation to Cy¹.

Where desired, two R¹⁰ substituents may be linked together to form a cyclic group such as a cyclic ether, e.g. a C₁₋₆alkylenedioxy group such as
10 methylenedioxy or ethylenedioxy.

It will be appreciated that where two or more R¹⁰ substituents are present, these need not necessarily be the same atoms and/or groups. In general, the substituent(s) may be present at any available ring position on the aromatic or
15 heteroaromatic group represented by the group Cy¹.

The substituted aromatic or heteroaromatic group represented by Ar in compounds of the invention may be any aromatic or heteroaromatic group as hereinbefore described for Cy¹. Optional substituents which may be present
20 include those R¹⁰ atoms and groups as generally or particularly described in relation to Cy¹ aromatic and heteroaromatic groups.

The presence of certain substituents in the compounds of formula (1) may enable salts of the compounds to be formed. Suitable salts include
25 pharmaceutically acceptable salts, for example acid addition salts derived from inorganic or organic acids, and salts derived from inorganic and organic bases.

Acid addition salts include hydrochlorides, hydrobromides, hydroiodides,
30 alkylsulfonates, e.g. methanesulfonates, ethanesulfonates, or isothionates, arylsulfonates, e.g. *p*-toluenesulfonates, besylates or napsylates,

phosphates, sulphates, hydrogen sulphates, acetates, trifluoroacetates, propionates, citrates, maleates, fumarates, malonates, succinates, lactates, oxalates, tartrates and benzoates.

- 5 Salts derived from inorganic or organic bases include alkali metal salts such as sodium or potassium salts, alkaline earth metal salts such as magnesium or calcium salts, and organic amine salts such as morpholine, piperidine, dimethylamine or diethylamine salts.
- 10 Particularly useful salts of compounds according to the invention include pharmaceutically acceptable salts, especially acid addition pharmaceutically acceptable salts.

When in compounds of formula (1) n is the integer 1, Alk^1 is preferably a
15 $-\text{CH}_2\text{CH}_2-$ chain or more especially is $-\text{CH}_2-$.

In one class of compounds of formula (1) n is zero.

- Particularly preferred Cy^1 optionally substituted cycloaliphatic groups include
20 optionally substituted C_{3-7} cycloalkyl groups, especially cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl groups. Cy^1 is in particular a cyclopropyl group.

- Each of these preferred Cy^1 cycloalkyl groups may be unsubstituted. When
25 substituents are present these may in particular include halogen atoms, especially fluorine, chlorine or bromine atoms, or C_{1-6} alkyl groups, especially C_{1-3} alkyl groups, most especially a methyl group, or a halo C_{1-6} alkyl group, especially a fluoro C_{1-6} alkyl group, most especially a $-\text{CF}_3$ group, or a C_{1-6} alkoxy, especially methoxy, ethoxy, propoxy or i-propoxy group, or a halo C_{1-6} alkoxy, especially a fluoro C_{1-6} alkoxy, most especially a $-\text{OCF}_3$ group, or a
30 cyano ($-\text{CN}$), esterified carboxyl, especially $-\text{CO}_2\text{CH}_3$ or $-\text{CO}_2\text{C}(\text{CH}_3)_3$, nitro

(-NO₂), amino (-NH₂), substituted amino, especially -NHCH₃ or -N(CH₃)₂, -C(O)R⁶, especially -C(O)CH₃, or -N(R⁶)C(O)R⁷, especially -NHCOCH₃ group.

- 5 Particularly preferred Cy¹ aromatic groups include optionally substituted phenyl groups. Particularly preferred heteroaromatic groups include optionally substituted monocyclic heteroaromatic groups, especially optionally substituted five- or six-membered heteroaromatic groups containing one, two, three or four heteroatoms selected from oxygen, sulphur
- 10 or nitrogen atoms. Particularly preferred optionally substituted monocyclic heteroaromatic groups include optionally substituted furyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, pyridyl, pyrimidinyl or triazinyl group. In a further preference, the heteroaromatic group may be an eight- to thirteen-membered bicyclic fused ring containing one or two oxygen, sulphur or nitrogen atoms.
- 15 Particularly useful groups of this type include optionally substituted indolyl groups.

- Particularly preferred optional substituents which may be present on Cy¹ aromatic or heteroaromatic groups include one, two or three atoms or groups
- 20 -R^{10a} or -L⁶Alk⁵(R^{10a})_r, as hereinbefore defined. Particularly useful optional substituents include halogen atoms, especially fluorine, chlorine or bromine atoms, or C₁₋₆alkyl groups, especially C₁₋₃alkyl groups, most especially a methyl group, or a haloC₁₋₆alkyl group, especially a fluoroC₁₋₆alkyl group, most especially a -CF₃ group, or a C₁₋₆alkoxy, especially methoxy, ethoxy,
- 25 propoxy or i-propoxy group, or a haloC₁₋₆alkoxy, especially a fluoroC₁₋₆alkoxy, most especially a -OCF₃ group, or a cyano (-CN), carboxyl (-CO₂H), esterified carboxyl (-CO₂Alk⁶), especially -CO₂CH₃, -CO₂CH₂CH₃, or -CO₂C(CH₃)₃, nitro (-NO₂), amino (-NH₂), substituted amino, especially -NHCH₃ or -N(CH₃)₂, -COR¹¹, especially -COCH₃, or -N(R¹²)COR¹¹,
- 30 especially -NHCOCH₃ group.

Further preferred optional substituents which may be present on Cy¹ aromatic or heteroaromatic groups include groups of formula $-L^6Alk^5(R^{10a})_r$ in which r is the integer 1 or 2, L^6 is a covalent bond or an $-O-$ or $-S-$ atom or a $-N(R^3)-$, especially $-NH-$ or $-N(CH_3)-$, $-C(O)-$, $-C(S)-$, $-C(O)O-$, $-OC(O)-$, $-N(R^3)CO-$, especially $-NHCO-$, or $-CON(R^3)-$, especially $-CHNH-$ group, Alk⁵ is a C₁₋₆alkyl chain, especially a $-CH_2-$, $-CH_2CH_2-$, $-CH_2CH_2CH_2-$ or $-CH_2CH_2CH_2CH_2-$ chain and R^{10a} is a hydroxyl or substituted hydroxyl group, especially a $-OCH_3$, $-OCH_2CH_3$ or $-OCH(CH_3)_2$ group or a $-NH_2$ or substituted amino group, especially a $-N(CH_3)_2$ or $-N(CH_2CH_3)_2$ group or a $-$

5 Het group, especially an optionally substituted monocyclic C₅₋₇carbocyclic group containing one, two or three $-O-$, $-S-$, $-N(R^{12})-$, especially $-NH-$ or $-N(CH_3)-$ or $-C(O)-$ groups within the ring structure as previously described, most especially an optionally substituted pyrrolidinyl, imidazolidinyl, piperidinyl, e.g. N-methylpiperidinyl, morpholinyl, thiomorpholinyl or

10 piperazinyl group or R^{10a} is an optionally substituted heteroaromatic group, especially a five- or six-membered monocyclic heteroaromatic group containing one, two, three or four heteroatoms selected from oxygen, sulphur or nitrogen atoms, such as optionally substituted pyrrolyl, furyl, thienyl, imidazolyl, triazolyl, pyridyl, pyrimidinyl, triazinyl, pyridazinyl, or pyrazinyl

15 group. Particularly preferred optional substituents on the $-Het$ groups just described include hydroxyl ($-OH$) and carboxyl ($-CO_2H$) groups or those preferred optional substituents just described in relation to the group Cy¹, especially when Cy¹ is a cycloalkyl group.

20

In one particularly preferred group of compounds of formula (1) Cy¹ is an optionally substituted phenyl group, especially a phenyl group optionally substituted by one, two or three substituents where at least one, and preferably two substituents are located *ortho* to the bond joining Cy¹ to the remainder of the compound of formula (1). Particularly preferred *ortho* substituents include halogen atoms, especially fluorine or chlorine atoms, or

25 C₁₋₃alkyl groups, especially methyl groups, C₁₋₃alkoxy groups, especially

30

methoxy, haloC₁₋₃alkyl groups, especially -CF₃, haloC₁₋₃alkoxy groups, especially -OCF₃, or cyano (-CN), groups. In this class of compounds a second or third optional substituent when present in a position other than the *ortho* positions of the ring Cy¹ may be preferably an atom or group -R^{10a} or -L⁶Alk⁵(R^{10a})_r, as herein generally and particularly described. In another preference, the Cy¹ phenyl group may have a substituent *para* to the bond joining Cy¹ to the remainder of the compound of formula (1). Particular *para* substituents include those particularly preferred *ortho* substituents just described. Where desired, the *para* substituent may be present with other *ortho* or *meta* substituents as just mentioned.

Particularly preferred Ar aromatic groups in compounds of formula (1) include optionally substituted phenyl groups. Particularly preferred heteroaromatic groups include optionally substituted monocyclic heteroaromatic groups, especially optionally substituted five- or six-membered heteroaromatic groups containing one, two, three or four heteroatoms selected from oxygen, sulphur or nitrogen atoms. Particularly preferred optionally substituted monocyclic heteroaromatic groups include optionally substituted furyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, pyridyl, pyrimidinyl or triazinyl group.

Particularly preferred optional substituents which may be present on Ar aromatic or heteroaromatic groups include atoms or groups -R^{10a} or -L⁶Alk⁵(R^{10a})_r, as hereinbefore defined. Particularly useful optional substituents include halogen atoms, especially fluorine, chlorine or bromine atoms, or C₁₋₆alkyl groups, especially C₁₋₃alkyl groups, most especially a methyl group, or a haloC₁₋₆alkyl group, especially a fluoroC₁₋₆alkyl group, most especially a -CF₃ group, or a C₁₋₆alkoxy, especially methoxy, ethoxy, propoxy or i-propoxy group, or a haloC₁₋₆alkoxy, especially a fluoroC₁₋₆alkoxy, most especially a -OCF₃ group, or a cyano (-CN), esterified carboxyl, especially -CO₂CH₃ or -CO₂C(CH₃)₃, nitro (-NO₂), amino (-NH₂), substituted amino, especially -

NHCH₃ or -N(CH₃)₂, -COR¹¹, especially -COCH₃, or -N(R¹²)COR¹¹, especially -NHCOCH₃ group.

5 Particularly useful Ar groups in compounds of formula (1) include phenyl and mono- or disubstituted phenyl groups in which each substituent is in particular a -R^{10a} or -L⁶Alk⁵(R^{10a})_r atom or group as just defined and is especially a halogen atom or a C₁₋₃alkyl, C₁₋₃alkoxy or -CN group

10 Particular examples of Alk² when present in compounds of the invention include -CH₂-, -CH₂CH₂-, -C(CH₃)₂- and -CH(CH₃)CH₂-.

15 In compounds of the invention, m may be selected to vary the ring size from a ring having, in addition to the nitrogen atom, a minimum of 3 carbon atoms up to 7 carbon atoms. Particularly advantageous rings are those wherein m is the integer 1 or 2.

Each substituent R^d may be present on any ring carbon atom. In one particular class of compounds of the invention one or two R^d substituents are present.

20

Particular R^d substituents include -OH, -CH₂OH, -CH(CH₃)OH and -C(CH₃)₂OH groups.

25 Particularly useful compounds of the invention include each of the compounds described in the Examples hereinafter, and the salts, solvates, hydrates and N-oxides thereof.

30 Compounds according to the invention are potent and selective inhibitors of p38 kinases, including all isoforms and splice variants thereof. More specifically the compounds of the invention are inhibitors of p38 α , p38 β and p38 β 2. The ability of the compounds to act in this way may be simply

determined by employing tests such as those described in the Examples hereinafter.

The compounds of formula (1) are of use in modulating the activity of p38
5 kinases and in particular are of use in the prophylaxis and treatment of any p38 kinase mediated diseases or disorders in a human, or other mammal. The invention extends to such a use and to the use of the compounds for the manufacture of a medicament for treating such diseases or disorders. Further the invention extends to the administration to a human an effective amount of
10 a p38 inhibitor for treating any such disease or disorder.

The invention also extends to the prophylaxis or treatment of any disease or disorder in which p38 kinase plays a role including conditions caused by excessive or unregulated pro-inflammatory cytokine production including for
15 example excessive or unregulated TNF, IL-1, IL-6 and IL-8 production in a human, or other mammal. The invention extends to such a use and to the use of the compounds for the manufacture of a medicament for treating such cytokine-mediated diseases or disorders. Further the invention extends to the administration to a human an effective amount of a p38 inhibitor for treating
20 any such disease or disorder.

Diseases or disorders in which p38 kinase plays a role either directly or via pro-inflammatory cytokines including the cytokines TNF; IL-1, IL-6 and IL-8 include without limitation autoimmune diseases, inflammatory diseases,
25 destructive-bone disorders, proliferative disorders, neurodegenerative disorders, viral diseases, allergies, infectious diseases, heart attacks, angiogenic disorders, reperfusion/ischemia in stroke, vascular hyperplasia, organ hypoxia, cardiac hypertrophy, thrombin-induced platelet aggregation and conditions associated with prostaglandin endoperoxidase synthetase-2
30 (COX-2).

Autoimmune diseases which may be prevented or treated include but are not limited to rheumatoid arthritis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, multiple sclerosis, diabetes, glomerulonephritis, systemic lupus erythematosus, scleroderma, chronic thyroiditis, Grave's disease, 5 hemolytic anemia, autoimmune gastritis, autoimmune neutropenia, thrombocytopenia, chronic active hepatitis, myasthenia gravis, atopic dermatitis, graft vs. host disease or psoriasis.

10 The invention further extends to the particular autoimmune disease rheumatoid arthritis.

Inflammatory diseases which may be prevented or treated include but are not limited to asthma, allergies, respiratory distress syndrome or acute or chronic pancreatitis.

15

Destructive bone disorders which may be prevented or treated include but are not limited to osteoporosis, osteoarthritis and multiple myeloma-related bone disorder.

20 Proliferative diseases which may be prevented or treated include but are not limited to acute or chronic myelogenous leukemia, Kaposi's sarcoma, metastatic melanoma and multiple myeloma.

25 Neurodegenerative diseases which may be prevented or treated include but are not limited to Parkinson's disease, Alzheimer's disease, cerebral ischemias or neurodegenerative disease caused by traumatic injury.

30 Viral diseases which may be prevented or treated include but are not limited to acute hepatitis infection (including hepatitis A, hepatitis B and hepatitis C), HIV infection and CMV retinitis.

Infectious diseases which may be prevented or treated include but are not limited to septic shock, sepsis and Shigellosis.

5 In addition, p38 inhibitors of this invention also exhibit inhibition of expression of inducible pro-inflammatory proteins such as prostaglandin endoperoxidase synthetase-2, otherwise known as cyclooxygenase-2 (COX-2) and are therefore of use in therapy. Pro-inflammatory mediators of the cyclooxygenase pathway derived from arachidonic acid are produced by inducible COX-2 enzyme. Regulation of COX-2 would regulate these pro-inflammatory mediators such as prostaglandins, which affect a wide variety of cells and are important and critical inflammatory mediators of a wide variety of disease states and conditions. In particular these inflammatory mediators have been implicated in pain, such as in the sensitization of pain receptors, or edema. Accordingly additional p38 mediated conditions which may be prevented or treated include edema, analgesia, fever and pain such as neuromuscular pain, headache, dental pain, arthritis pain and pain caused by cancer.

20 As a result of their p38 inhibitory activity, compounds of the invention have utility in the prevention and treatment of diseases associated with cytokine production including but not limited to those diseases associated with TNF, IL-1, IL-6 and IL-8 production.

25 Thus TNF mediated diseases or conditions include for example rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis and other arthritic conditions, sepsis, septic shock syndrome, adult respiratory distress syndrome, cerebral malaria, chronic pulmonary inflammatory disease, silicosis, pulmonary sarcoidosis, bone resorption disease, reperfusion injury, graft vs. host reaction, allograft rejections, fever and myalgias due to infection, cachexia secondary to infection, AIDS, ARC or malignancy, keloid formation, scar tissue formation, Crohn's disease, ulcerative colitis, pyresis,

viral infections such as HIV, CMV, influenza and herpes; and veterinary viral infections, such as lentivirus infections, including but not limited to equine infectious anemia virus, caprine arthritis virus, visna virus or maedi virus; or retrovirus infections, including feline immunodeficiency virus, bovine immunodeficiency virus or canine immunodeficiency virus.

Compounds of the invention may also be used in the treatment of viral infections, where such viruses elicit TNF production *in vivo* or are sensitive to upregulation by TNF. Such viruses include those that produce TNF as a result of infection and those that are sensitive to inhibition, for instance as a result of decreased replication, directly or indirectly by the TNF inhibiting compounds of the invention. Such viruses include, but are not limited to, HIV-1, HIV-2 and HIV-3, Cytomegalovirus (CMV), Influenza, adenovirus and the Herpes group of viruses such as Herpes Zoster and Herpes Simplex.

IL-1 mediated diseases or conditions include for example rheumatoid arthritis, osteoarthritis, psoriatic arthritis, traumatic arthritis, rubella arthritis, inflammatory bowel disease, stroke, endotoxemia and/or toxic shock syndrome, inflammatory reaction induced by endotoxin, diabetes, pancreatic β -cell disease, Alzheimer's disease, tuberculosis, atherosclerosis, muscle degeneration and cachexia.

IL-8 mediated diseases and conditions include for example those characterized by massive neutrophil infiltration such as psoriasis, inflammatory bowel disease, asthma, cardiac, brain and renal reperfusion injury, adult respiratory distress syndrome, thrombosis and glomerulonephritis. The increased IL-8 production associated with each of these diseases is responsible for the chemotaxis of neutrophils into inflammatory sites. This is due to the unique property of IL-8 (in comparison to TNF, IL-1 and IL-6) of promoting neutrophil chemotaxis and activation.

Therefore, inhibition of IL-8 production would lead to a direct reduction in neutrophil infiltration.

It is also known that both IL-6 and IL-8 are produced during rhinovirus (HRV) infections and contribute to the pathogenesis of the common cold and exacerbation of asthma associated with HRV infection [Turner *et al*, Clin. Infec. Dis., 1997, 26, 840; Grunberg *et al*, Am. J. Crit. Care Med. 1997, 155, 1362; Zhu *et al*, J. Clin. Invest. 1996, 97, 421]. It has also been demonstrated *in vitro* that infection of pulmonary epithelial cells (which represent the primary site of infection by HRV) with HRV results in production of IL-6 and IL-8 [Sabauste *et al*, J. Clin. Invest. 1995, 96, 549]. Therefore, p38 inhibitors of the invention may be used for the treatment or prophylaxis of the common cold or respiratory viral infection caused by human rhinovirus infection (HRV), other enteroviruses, coronavirus, influenza virus, parainfluenza virus, respiratory syncytial virus or adenovirus infection.

For the prophylaxis or treatment of a p38 or pro-inflammatory cytokine mediated disease the compounds according to the invention may be administered to a human or mammal as pharmaceutical compositions, and according to a further aspect of the invention we provide a pharmaceutical composition which comprises a compound of formula (1) together with one or more pharmaceutically acceptable carriers, excipients or diluents.

Pharmaceutical compositions according to the invention may take a form suitable for oral, buccal, parenteral, nasal, topical, ophthalmic or rectal administration, or a form suitable for administration by inhalation or insufflation.

For oral administration, the pharmaceutical compositions may take the form of, for example, tablets, lozenges or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents

(e.g. pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose); fillers (e.g. lactose, microcrystalline cellulose or calcium hydrogen phosphate); lubricants (e.g. magnesium stearate, talc or silica); disintegrants (e.g. potato starch or sodium glycollate); or wetting agents (e.g.

- 5 sodium lauryl sulphate). The tablets may be coated by methods well known in the art. Liquid preparations for oral administration may take the form of, for example, solutions, syrups or suspensions, or they may be presented as a dry product for constitution with water or other suitable vehicle before use. Such liquid preparations may be prepared by conventional means with
- 10 pharmaceutically acceptable additives such as suspending agents, emulsifying agents, non-aqueous vehicles and preservatives. The preparations may also contain buffer salts, flavouring, colouring and sweetening agents as appropriate.

- 15 Preparations for oral administration may be suitably formulated to give controlled release of the active compound.

For buccal administration the compositions may take the form of tablets or lozenges formulated in conventional manner.

20

- The compounds for formula (1) may be formulated for parenteral administration by injection e.g. by bolus injection or infusion. Formulations for injection may be presented in unit dosage form, e.g. in glass ampoule or multi dose containers, e.g. glass vials. The compositions for injection may
- 25 take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilising, preserving and/or dispersing agents. Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle, e.g. sterile pyrogen-free water, before use.

30

In addition to the formulations described above, the compounds of formula (1) may also be formulated as a depot preparation. Such long acting formulations may be administered by implantation or by intramuscular injection.

5

For nasal administration or administration by inhalation, the compounds for use according to the present invention are conveniently delivered in the form of an aerosol spray presentation for pressurised packs or a nebuliser, with the use of suitable propellant, e.g. dichlorodifluoromethane, trichloro-
10 fluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas or mixture of gases.

The compositions may, if desired, be presented in a pack or dispenser device which may contain one or more unit dosage forms containing the active
15 ingredient. The pack or dispensing device may be accompanied by instructions for administration.

For topical administration the compounds for use according to the present invention may be conveniently formulated in a suitable ointment containing
20 the active component suspended or dissolved in one or more pharmaceutically acceptable carriers. Particular carriers include, for example, mineral oil, liquid petroleum, propylene glycol, polyoxyethylene, polyoxypropylene, emulsifying wax and water. Alternatively the compounds for use according to the present invention may be formulated in a suitable
25 lotion containing the active component suspended or dissolved in one or more pharmaceutically acceptable carriers. Particular carriers include, for example mineral oil, sorbitan monostearate, polysorbate 60, cetyl esters wax, cetearyl alcohol, benzyl alcohol, 2-octyldodecanol and water.

30 For ophthalmic administration the compounds for use according to the present invention may be conveniently formulated as microionized

suspensions in isotonic, pH adjusted sterile saline, either with or without a preservative such as bactericidal or fungicidal agent, for example phenylmercuric nitrate, benzylalkonium chloride or chlorhexidine acetate. Alternatively for ophthalmic administration compounds may be formulated in
5 an ointment such as petrolatum.

For rectal administration the compounds for use according to the present invention may be conveniently formulated as suppositories. These can be prepared by mixing the active component with a suitable non-irritating
10 excipient which is solid at room temperature but liquid at rectal temperature and so will melt in the rectum to release the active component. Such materials include for example cocoa butter, beeswax and polyethylene glycols.


15 The quantity of a compound of the invention required for the prophylaxis or treatment of a particular condition will vary depending on the compound chosen, and the condition of the patient to be treated. In general, however, daily dosages may range from around 100ng/kg to 100mg/kg e.g. around 0.01mg/kg to 40mg/kg body weight for oral or buccal administration, from
20 around 10ng/kg to 50mg/kg body weight for parenteral administration and around 0.05mg to around 1000mg e.g. around 0.5mg to around 1000mg for nasal administration or administration by inhalation or insufflation.

25 The compounds of the invention may be prepared by a number of processes as generally described below and more specifically in the Examples hereinafter. In the following process description, the symbols Ar, Cy¹, Alk¹, n, R^d, p, m and Y when used in the formulae depicted are to be understood to represent those groups described above in relation to formula (1) unless
30 otherwise indicated. In the reactions described below, it may be necessary to protect reactive functional groups, for example hydroxy, amino, thio or

carboxy groups, where these are desired in the final product, to avoid their unwanted participation in the reactions. Conventional protecting groups may be used in accordance with standard practice [see, for example, Green, T. W. in "Protective Groups in Organic Synthesis", John Wiley and Sons, 1999].

- 5 In some instances, deprotection may be the final step in the synthesis of a compound of formula (1) and the processes according to the invention described hereinafter are to be understood to extend to such removal of protecting groups.
- 10 Thus according to a further aspect of the invention a compound of formula (1) in which Y is a $-C(O)-$ group may be prepared from a carboxylic acid of formula (2) or ester of formula (5) according to amide bond forming reactions well known to those skilled in the art. Such reactions are set forth in references such as March's Advanced Organic Chemistry (John Wiley and
- 15 Sons 1992), Larock's Comprehensive Organic Transformations (VCH Publishers Inc., 1992) and Comprehensive Organic Functional Group Transformations, Ed. Katritzky et al, Volumes 1-8, 1984 and Volumes 1-11, 1994 (Pergamon). Examples of such methods that may be employed to give compounds of formula (1a) are set out, but not limited to, the reactions in
- 20 Scheme 1 and Scheme 2 below.


Scheme 1



Thus amides of formula (1a) may be formed by reaction of a carboxylate salt of formula (2) [where M^+ is metal counter ion such as a sodium or lithium ion or is alternatively an ammonium or trialkylammonium counter ion] with an amine of formula (3) in the presence of a coupling reagent such as a carbodiimide e.g. 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (EDC) or N,N'-dicyclohexylcarbodiimide optionally in the presence of a base such as an amine e.g. triethylamine or N-methylmorpholine. These reactions may be performed in a solvent such as an amide solvent e.g. N,N-dimethylformamide (DMF) or an ether e.g. a cyclic ether such as tetrahydrofuran or 1,4-dioxane or a halogenated solvent such as dichloromethane at around ambient temperature to 60°C. In another procedure a pentafluorophenyl ester of formula (4) may be prepared by reaction of a carboxylic acid of formula (2) with pentafluorophenol in the presence of a coupling reagent such as 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide in a solvent such as an amide solvent e.g. DMF at around ambient temperature. Amides of formula (1a) can then be prepared by reaction of the pentafluorophenyl ester with amines of formula (3) in an organic solvent such as a halogenated hydrocarbon e.g. dichloromethane at around ambient temperature. The intermediate acids of formula (2) may be prepared by hydrolysis of esters of formula (5) using a base such as an alkali metal hydroxide e.g. sodium hydroxide or lithium hydroxide in water and a solvent such as tetrahydrofuran or an alcohol such as ethanol at a temperature from around ambient to reflux.


Amides of formula (1a) can also be prepared directly from esters of formula (5) by heating with an amine of formula (3) up to the reflux temperature of the amine optionally in the presence of a solvent such as 2-ethoxyethanol either at atmospheric pressure or under pressure in a sealed tube (Scheme 2)

Scheme 2



The intermediate esters of formula (5) may be prepared by the methods set out in Scheme 3 below. In the Scheme the preparation of an ethyl ester is specifically shown, but it will be appreciated that other esters may be obtained by simply varying the ester starting material and if appropriate any reaction conditions:

Scheme 3



Thus in Scheme 3 a compound of formula (5a) or (5b) may be prepared by reaction of a compound of formulae (6) or (7) with an amine ArNH_2 in the presence of a palladium catalyst. The reaction may be conveniently carried out in a solvent such as toluene at an elevated temperature, eg the reflux temperature, using a catalyst such as tris(dibenzylideneacetone)dipalladium(0), a phosphine ligand such as 2,2'-bis(diphenylphosphino)-1,1'-binaphthyl and a base such as caesium carbonate. Where desired, alternative reaction conditions may be used, for example as described in the literature [Luker et al. Tet. Lett. (2001) 41, 7731; Buchwald S.L. J.Org.Chem. (2000) 65 1144; Hartwig J.F. Angew. Chem. Int. Ed. Engl. (1998) 37, 2046].

Intermediates of formula (7) may be prepared by reaction of a compound of formula (8) with an alkylating agent of formula $\text{Cy}^1(\text{Alk}^1)_n\text{Z}$, where Z is a leaving group such as a halogen atom, e.g. a chlorine, bromine or iodine atom or a sulphonyloxy group such as an alkylsulphonyloxy e.g. trifluoromethylsulphonyloxy or arylsulphonyloxy e.g. phenylsulphonyloxy group.

The reaction may be performed in the presence of a solvent, for example a substituted amide such as dimethylformamide, optionally in the presence of a base, for example an inorganic base such as sodium hydride, or an organic base such as an organic amine, e.g. a cyclic amine such as 1,5-diazabicyclo[4.3.0]non-5-ene or a resin bound organic amine such as resin bound 2-*tert*-butylimino-2-diethylamino-1,3-dimethyl-perhydro-1,3,2-diazaphosphorine (PS-BEMP), at an elevated temperature, for example 80 to 100°C.

Intermediates of formula (6) may be prepared by the reaction of a compound of formula (8) with a boronic acid of formula $\text{Cy}^1\text{B}(\text{OH})_2$ in which Cy^1 is an aryl or heteroaryl group. The reaction may be performed in an organic solvent, for example a halogenated hydrocarbon such as dichloromethane or


dichloroethane in the presence of a copper reagent, for example a copper (I) salt such as CuI or for example a copper (II) reagent such as copper (II) acetate, optionally in the presence of an oxidant, for example 2,2,6,6-tetramethylpiperidine-1-oxide or pyridine-N-oxide, optionally in the presence
5 of a base, for example an organic amine such as an alkylamine, e.g. triethylamine or an aromatic amine, e.g. pyridine at a temperature from around ambient to the reflux temperature [see for example Chan, D.T. *et al*/Tetrahedron Letters, 1998, 2933; Lam, P.Y.S. *et al*, Tetrahedron Letters, 2001, 3415]

10

Intermediates of formula (6) where Cy¹ is an aryl or heteroaryl group may also be prepared by nucleophilic aromatic substitution of a suitably activated aryl or heteroaryl halide with a compound of formula (8). The reaction may be performed in a dialkylamide solvent such as DMF in the presence of a base
15 such as a metal hydride e.g. sodium hydride at a temperature from around ambient to 100°C. Suitably activated aryl or heteroaryl halides are those with an electron withdrawing substituent such as a nitro, cyano or ester group e.g. a chloro- or fluoro-nitrobenzene or 2-chloro-5-nitropyridine. Alternatively a nitrogen containing heteroaryl halide can be activated to nucleophilic
20 substitution by N-oxidation e.g. 2-chloropyridine N-oxide.

It will be appreciated that if desired the reactions just described may be carried out in the reverse order so that the amination using ArNH₂ is performed first with the intermediate of formula (8) followed by
25 alkylation/arylation to yield the compound of formula (5). It may be necessary to protect the nitrogen function of compounds of formula (8) during the course of these reactions. Such protection may be achieved by O-alkylation with an alkyl halide e.g. cyclopropylmethyl bromide or an arylalkyl bromide e.g. benzyl bromide as shown in Scheme 4.

30 Scheme 4



- The O-alkylation reaction may be performed in an organic solvent such as DMF in the presence of a base, for example an inorganic base such as Cs_2CO_3 or an organic base such as an amine e.g. a cyclic amine such as 1,5-diazabicyclo[4.3.0]non-5-ene at an elevated temperature e.g. 80 to 100°C to give a compound of formula (13). Reaction of the protected compound (13) with ArNH_2 under palladium catalysis can then be performed as previously described to give a compound of formula (14). Deprotection can then be achieved by treating a solution of this compound in an alcohol e.g. MeOH with a mineral acid such as concentrated HCl at an elevated temperature e.g. the reflux temperature to give a compound of formula (15). Alternatively when benzyl protection is employed then this group may be removed reductively by treating a solution of compound (14) in an organic solvent such as EtOH using a palladium or platinum catalyst e.g. palladium on carbon or PtO_2 under an elevated pressure of hydrogen at a temperature from around ambient to 60°C . Compounds of formula (15) can then undergo alkylation/arylation reactions as previously described to give compounds of formula (5).
- Intermediate pyridinones of formula (8) may be prepared from pyridine N-oxides of formula (9) by sequential reaction with an anhydride, for example acetic anhydride at an elevated temperature, for example the reflux temperature followed by reaction with an inorganic base, for example a

carbonate such as aqueous potassium carbonate in a solvent such as an ether for example a cyclic ether e.g. tetrahydrofuran at around ambient temperature. Alternatively the reaction may be performed using trifluoroacetic anhydride in dimethylformamide from 0°C to ambient temperature conditions
5 [see for example Konno et al., *Heterocycles* (1986) 24, 2169].

Pyridine N-oxides of formula (9) may be formed by oxidation of pyridines of formula (10) using an oxidising agent such as hydrogen peroxide in the presence of an acid such as acetic acid, at an elevated temperature, for
10 example around 70°C to 80°C, or alternatively by reaction with a peracid such as peracetic acid or m-chloroperoxybenzoic acid in a solvent, such as a halogenated hydrocarbon e.g. dichloromethane or an alcohol e.g. tert-butanol at a temperature from the ambient temperature to the reflux temperature.


15 Intermediate pyridines of formula (10) in Scheme 3 may be obtained by standard methods such as for example by the Sandmeyer reaction. Thus for example a bromide of formula (10) may be prepared by treatment of an aryl amine of formula (11) with an alkyl nitrite, for example t-butyl nitrite and a copper salt, for example copper (II) bromide in the presence of a solvent, for
20 example a nitrile such as acetonitrile at a temperature from about 0° to around 65°C.

Amines of formula (11) may be formed from 2-halopyridine-3-carbonitriles of formula (12) by reaction with a reagent such as ethyl 2-mercaptoacetate. The
25 reaction may be performed in the presence of a solvent such as a substituted amide for example dimethylformamide or an ether e.g. a cyclic ether such as tetrahydrofuran or alcohol such as ethanol in the presence of a base, for example an inorganic base such as sodium carbonate or a hydride e.g. sodium hydride or an organic base such as 1,5-diazabicyclo[4.3.0]non-5-ene
30 or a trialkylamine such as triethylamine at a temperature between about 0°C

and 100°C. The carbonitrile starting materials are readily available or may be obtained from known compounds using standard procedures.

In another process intermediate esters of formula (6a) may be prepared by the reactions set out in Scheme 5. In the Scheme below R²⁰ represents an ester or nitrile and LG represents a leaving group such as a halogen e.g. chlorine or bromine or sulfonyloxy group such as an alkylsulfonyloxy group e.g. trifluoromethylsulfonyloxy or arylsulfonyloxy group e.g. p-toluenesulfonyloxy group.

10 Scheme 5



Thus in step (A) of the reaction scheme a compound of formulae (17) or (18), where Rx is an optionally substituted alkyl group e.g. methyl and W is a hydrogen atom metal ion or amine salt, may be reacted with a thioamide of formula (19). The reaction may be performed in the presence of a base. Appropriate bases may include, but are not limited to, lithium bases such as n-butyl or t-butyl lithium or lithium diisopropylamide (LDA), or silazanes e.g. lithium hexamethyldisilazane (LiHMDS) or sodium hexamethyldisilazane (NaHMDS), or a carbonate, e.g. potassium carbonate, an alkoxide, e.g. sodium ethoxide, sodium methoxide, potassium t-butoxide, a hydroxide e.g. NaOH or a hydride, e.g. sodium hydride, or an organic amine e.g. triethylamine or N,N-diisopropylethylamine or a cyclic amine, such as N-methylmorpholine or pyridine. The reaction may be performed in an organic solvent such as an amide e.g. a substituted amide such as

dimethylformamide, an ether e.g. a cyclic ether such as tetrahydrofuran or dioxane or an alcohol e.g. methanol, ethanol or propanol or acetonitrile, at a temperature from ambient to the reflux temperature. In one particular aspect of the process the reaction is achieved using an alkoxide base, especially sodium ethoxide or sodium methoxide in an alcoholic solvent, especially ethanol at reflux temperature.

Intermediates of formula (17), where not commercially available, may be prepared using standard methodology. (See, for example, Mir Hedayatullah, J. Heterocyclic Chem., 18, 339, (1981)). Similarly, intermediates of formula (18) where not commercially available, may be prepared using standard methodology. For example they may be prepared *in-situ* by reaction of an acetate e.g. ethyl acetate with a base such as sodium methoxide followed by addition of a formate e.g. methyl formate.

15

In a similar manner, Intermediates of formula (19), if not commercially available, may be prepared using methods known to those skilled in the art (see, for example Adhikari et al, Aust. J. Chem., 52, 63-67, (1999)). For example, an isothiocyanate of formula Cy^1NCS may be reacted with acetonitrile in the presence of a base e.g. NaHMDS in a suitable solvent e.g. tetrahydrofuran, optionally at a low temperature, e.g. around $-78^{\circ}C$. According to the nature of the group Cy^1 , the Intermediate of formula (19) may be prepared *in situ*, for example, using the methods as described herein, followed by subsequent addition of a compound of formulae (17) or (18).

25


During the course of this process an intermediate of formula (20) may be formed. If desired the intermediate may be isolated at the end of step (A) and subsequently reacted with intermediate (21) to form the desired amine (22). In some instances however it may be advantageous not to isolate the intermediate of formula (20) and reaction (B) may be carried out directly with the reaction mixture of step (A).

30

If a different solvent is used during the second stage of the process, it may be necessary to evaporate the solvent, *in vacuo*, from the first stage of the process before proceeding with the second stage. Once evaporated, the crude solids from step (A) may be used in the next stage or they may be purified, for example, by crystallisation, to yield an isolated intermediate, such as a compound of formula (20).

During step (B) of the process an intermediate of formula (21) may then be added to the reaction mixture or to the crude solids or purified product from step (A) in a suitable solvent. Suitable solvents include, but are not limited to, amides e.g. a substituted amide such as dimethylformamide, alcohols e.g. ethanol, methanol or isopropyl alcohol, ethers e.g. a cyclic ether such as tetrahydrofuran or dioxane or acetonitrile. The reaction may be performed at a temperature from ambient up to the reflux temperature.

During the course of step (B) an intermediate of formula (24):



may be observed or even isolated, depending upon the nature of the group R^{20} . The intermediate of formula (24) may be converted to a compound of formula (22) using the methods described above. In this situation it may be necessary to add a base, in order for the reaction to proceed to completion. Appropriate bases include carbonates e.g. caesium or potassium carbonate, or alkoxides e.g. potassium *t*-butoxide, or hydrides e.g. sodium hydride or organic amines e.g. triethylamine or *N,N*-diisopropylethylamine or cyclic amines, such as *N*-methylmorpholine or pyridine.

Amines of formula (22) can be converted to bromides of formula (23) by standard methods such as for example by the Sandmeyer reaction as previously described for compounds of formula (11). Compounds of formula (6a) can then be prepared from these bromides by the palladium catalysed
5 amination reactions already described.

It will be appreciated that Intermediates of formula (21) where not commercially available may be prepared using standard methods known to those skilled in the art. For example, alcohol groups may be converted into
10 leaving groups, such as halogen atoms or sulfonyloxy groups using conditions known to the skilled artisan. For example, an alcohol may be reacted with thionyl chloride in a halogenated hydrocarbon e.g., dichloromethane to yield the corresponding chloride. A base e.g., triethylamine may also be used in the reaction.

15 It will be appreciated that in Scheme 5 when R20 is nitrile that a compound of formula (23a) may be prepared. Such nitriles are useful intermediates in the synthesis of intermediate carboxylic acids of formula (25a). This reaction may be performed by hydrolysis of the nitrile (23a) with a base such as a alkali metal
20 hydroxide e.g. an 2M aqueous solution of sodium hydroxide in an alcohol solvent such as methanol or ethanol at reflux.




25 It will be appreciated that intermediates, such as intermediates (17), (18), (19) or (21), if not available commercially, may also be prepared by methods known to those skilled in the art following procedures set forth in references such as Rodd's Chemistry of Carbon Compounds, Volumes 1-15 and Supplementals (Elsevier Science Publishers, 1989), Fieser and Fieser's

Reagents for Organic Synthesis, Volumes 1-19 (John Wiley and Sons, 1999), Comprehensive Heterocyclic Chemistry, Ed. Katritzky et al, Volumes 1-8, 1984 and Volumes 1-11, 1994 (Pergamon), Comprehensive Organic Functional Group Transformations, Ed. Katritzky et al, Volumes 1-7, 1995
 5 Pergamon), Comprehensive Organic Synthesis, Ed. Trost and Flemming, Volumes 1-9, (Pergamon, 1991), Encyclopedia of Reagents for Organic Synthesis Ed. Paquette, Volumes 1-8 (John Wiley and Sons, 1995), Larock's Comprehensive Organic Transformations (VCH Publishers Inc., 1989) and March's Advanced Organic Chemistry (John Wiley and Sons, 1992).

10

In another process amides of formula (1a) may be prepared by the reactions detailed in Scheme 6 below.

Scheme 6



15


Thus acids of formula (25) or (25a) may be converted to amides of formula (27) by reaction with amines of formula (3) in the presence of coupling reagents in the same way as previously described for the conversion of compounds (2) to amides of formula (1a). Alternatively the carboxylic acids
 20 may be converted to acid chlorides of formula (26) by reaction with a chlorinating agent such as oxalyl chloride optionally in the presence of a catalytic amount of DMF in a solvent such as a halogenated hydrocarbon e.g. dichloromethane or an ether e.g. a cyclic ether such as tetrahydrofuran at around ambient temperature. The resultant acid chlorides may then be

reacted with amines of formula (3) in a solvent such as a halogenated hydrocarbon e.g. dichloromethane in the presence of an amine base such as triethylamine at around ambient temperature to give amides of formula (27). Amides of formula (1a) may then be prepared from amides of formula (27)

5 using a palladium catalysed arylation procedure previously described in Scheme 1. During the course of the reactions described above it may be advantageous or necessary to protect the R^d substituents that may be present. Conventional protecting groups may be used in accordance with standard practice [see, for example, Green, T. W. in "Protective Groups in
10 Organic Synthesis", John Wiley and Sons, 1999]. In some instances, deprotection may be the final step in the synthesis of a compound of formula (1a) and the processes according to the invention described hereinafter are to be understood to extend to such removal of protecting groups.

15 According to a further aspect of the invention a compound of formula (1) in which Y is an $-S(O_2)-$ group may be prepared by the route set out in Scheme 7.

Scheme 7



20 Thus a compound of formula (29) can be obtained by reaction of a compound of formula (28) with a metal amide base such as sodium bis(trimethylsilyl)amide in a solvent such as an ether e.g. a cyclic ether such as tetrahydrofuran at a temperature of around 0°C and then adding di-*tert*-butyl dicarbonate in a solvent such as tetrahydrofuran and stirring at ambient
25 temperature. A compound of formula (1) can then be prepared by the following reaction sequence. A compound of formula (29) is treated with a

base such as an alkyl lithium, e.g. n-butyl lithium in a solvent such as an ether e.g. a cyclic ether such as tetrahydrofuran at a temperature of around – 78°C. Sulfur dioxide gas is bubbled through the reaction mixture before allowing the reaction to warm to room temperature. Solvents are removed *in vacuo* and the crude material dissolved in a solvent such as a halogenated hydrocarbon, e.g. dichloromethane and the mixture treated with a chlorinating reagent such as N-chlorosuccinimide at around ambient temperature. An amine of formula (3) can then be added to the reaction mixture to produce a compound of formula (30), where R = *t*-butoxycarbonyl.

5

10 A sulphonamide of formula (1) can then be prepared by treating a compound of formula (30) with an acid e.g. a mineral acid such as HCl or an organic acid such as trifluoroacetic acid in a solvent such as a halogenated hydrocarbon e.g. dichloromethane. Intermediates of formula (28) may be obtained by decarboxylation of compounds of formula (2) with an acid such

15 as a mineral acid e.g. HCl in a solvent such as an ether e.g. a cyclic ether e.g. tetrahydrofuran or 1,4-dioxane at a temperature from 50°C up to the reflux temperature.

Where in the general processes described above intermediates such as alkylating agents of formula $Cy^1(Alk^1)_nZ$, reagents of formula $HXCH_2CO_2Et$ and any other intermediates required in the synthesis of compounds of the invention are not available commercially or known in the literature, they may be readily obtained from simpler known compounds by one or more standard synthetic methods employing substitution, oxidation, reduction or cleavage

25 reactions. Particular substitution approaches include conventional alkylation, arylation, heteroarylation, acylation, thioacylation, halogenation, sulphonylation, nitration, formylation and coupling procedures. It will be appreciated that these methods may also be used to obtain or modify other intermediates and in particular compounds of formula (1) where appropriate

30 functional groups exist in these compounds. Particular examples of such methods are given in the Examples hereinafter.

Thus for example aromatic halogen substituents in the compounds may be subjected to halogen-metal exchange with a base, for example a lithium base such as n-butyl or t-butyl lithium, optionally at a low temperature, e.g. around
5 -78°C, in a solvent such as tetrahydrofuran and then quenched with an electrophile to introduce a desired substituent. Thus, for example, a formyl group may be introduced by using dimethylformamide as the electrophile, a thiomethyl group may be introduced by using dimethyldisulphide as the electrophile, an alcohol group may be introduced by using an aldehyde as
10 electrophile and an acid may be introduced by using carbon dioxide as electrophile. Aromatic acids of formula ArCO_2H may also be generated by quenching Grignard reagents of formula ArMgHal with carbon dioxide.

Aromatic acids of formula ArCO_2H generated by this method and acid
15 containing compounds in general may be converted to activated derivatives, e.g. acid halides by reaction with a halogenating agent such as a thionyl halide e.g. thionyl chloride, a phosphorous trihalide such as phosphorous trichloride or a phosphorous pentahalide such as phosphorous pentachloride optionally in an inert solvent such as an aromatic hydrocarbon e.g. toluene or
20 a chlorinated hydrocarbon e.g. dichloromethane at a temperature from about 0°C to the reflux temperature, or may be converted into Weinreb amides of formula $\text{ArC}(\text{O})\text{N}(\text{OMe})\text{Me}$ by conversion to the acid halide as just described and subsequent reaction with an amine of formula $\text{HN}(\text{OMe})\text{Me}$ or a salt thereof, optionally in the presence of a base such as an organic amine, e.g.
25 triethylamine in an inert solvent such as an aromatic hydrocarbon e.g. toluene or a chlorinated hydrocarbon e.g. dichloromethane at a temperature from about 0°C to ambient temperature.

Ester groups such as $-\text{CO}_2\text{Alk}^6$ and $-\text{CO}_2\text{R}^4$ in the compound of formula (1)
30 and intermediates thereto may be converted to the corresponding acid [$-\text{CO}_2\text{H}$] by acid- or base-catalysed hydrolysis depending on the nature of the

group Alk^6 or R^4 . Acid- or base-catalysed hydrolysis may be achieved for example by treatment with an organic or inorganic acid, e.g. trifluoroacetic acid in an organic solvent e.g. dichloromethane or a mineral acid such as hydrochloric acid in a solvent such as dioxan or an alkali metal hydroxide, 5 e.g. lithium hydroxide in an aqueous alcohol, e.g. aqueous methanol.

In a further example, $-\text{OR}^6$ [where R^6 represents an alkyl group such as methyl group] in compounds of formula (1) and intermediates thereto may be cleaved to the corresponding alcohol $-\text{OH}$ by reaction with boron tribromide in 10 a solvent such as a halogenated hydrocarbon, e.g. dichloromethane at a low temperature, e.g. around -78°C .

Alcohol $[-\text{OH}]$ groups may also be obtained by hydrogenation of a corresponding $-\text{OCH}_2\text{R}^{31}$ group (where R^{31} is an aryl group) using a metal 15 catalyst, for example palladium on a support such as carbon in a solvent such as ethanol in the presence of ammonium formate, cyclohexadiene or hydrogen, from around ambient to the reflux temperature. In another example, $-\text{OH}$ groups may be generated from the corresponding ester [e.g. $-\text{CO}_2\text{Alk}^6$] or aldehyde $[-\text{CHO}]$ by reduction, using for example a complex 20 metal hydride such as lithium aluminium hydride or sodium borohydride in a solvent such as methanol.

In another example, alcohol $-\text{OH}$ groups in the compounds may be converted to a corresponding $-\text{OR}^6$ group by coupling with a reagent R^6OH in a solvent 25 such as tetrahydrofuran in the presence of a phosphine, e.g. triphenylphosphine and an activator such as diethyl-, diisopropyl-, or dimethylazodicarboxylate.

Aminosulphonylamino $[-\text{NHSO}_2\text{NH}_2]$ groups in the compounds may be 30 obtained, in another example, by reaction of a corresponding amine $[-\text{NH}_2]$

with sulphamide in the presence of an organic base such as pyridine at an elevated temperature, e.g. the reflux temperature.

5 In another example compounds containing a $-NHCSR^7$ or $-CSNHR^7$ group may be prepared by treating a corresponding compound containing a $-NHCOR^7$ or $-CONHR^7$ group with a thiation reagent, such as Lawesson's Reagent or P_2S_5 , in an anhydrous solvent, for example a cyclic ether such as tetrahydrofuran, at an elevated temperature such as the reflux temperature.

10 In a further example amine ($-NH_2$) groups may be alkylated using a reductive alkylation process employing an aldehyde and a reducing agent. Suitable reducing agents include borohydrides for example sodium triacetoxyborohydride or sodium cyanoborohydride. The reduction may be carried out in a solvent such as a halogenated hydrocarbon, e.g.
15 dichloromethane, a ketone such as acetone, or an alcohol, e.g. ethanol, where necessary in the presence of an acid such as acetic acid at around ambient temperature. Alternatively, the amine and aldehyde may be initially reacted in a solvent such as an aromatic hydrocarbon e.g. toluene and then subjected to hydrogenation in the presence of a metal catalyst, for example
20 palladium on a support such as carbon, in a solvent such as an alcohol, e.g. ethanol.

In a further example, amine [$-NH_2$] groups in compounds of formula (1) and intermediates thereto may be obtained by hydrolysis from a corresponding
25 imide by reaction with hydrazine in a solvent such as an alcohol, e.g. ethanol at ambient temperature.

In another example, a nitro [$-NO_2$] group may be reduced to an amine [$-NH_2$], for example by catalytic hydrogenation using for example hydrogen in the
30 presence of a metal catalyst, for example palladium on a support such as carbon in a solvent such as an ether, e.g. tetrahydrofuran or an alcohol e.g.

methanol, or by chemical reduction using for example a metal, e.g. tin or iron, in the presence of an acid such as hydrochloric acid.

5 In a further example amine ($-\text{CH}_2\text{NH}_2$) groups in compounds of formula (1) and intermediates thereto may be obtained by reduction of nitriles ($-\text{CN}$), for example by catalytic hydrogenation using for example hydrogen in the presence of a metal catalyst, for example palladium on a support such as carbon, or Raney[®] nickel, in a solvent such as an ether e.g. a cyclic ether such as tetrahydrofuran or an alcohol e.g. methanol or ethanol, optionally in
10 the presence of ammonia solution at a temperature from ambient to the reflux temperature, or by chemical reduction using for example a metal hydride e.g. lithium aluminium hydride, in a solvent such as an ether e.g. a cyclic ether such as tetrahydrofuran, at a temperature from 0°C to the reflux temperature.

15 In another example, sulphur atoms in the compounds, for example when present in a group L^1 or L^2 may be oxidised to the corresponding sulfoxide or sulphone using an oxidising agent such as a peroxy acid, e.g. 3-chloroperoxybenzoic acid, in an inert solvent such as a halogenated hydrocarbon, e.g. dichloromethane, at around ambient temperature.

20

In a further example N-oxides of compounds of formula (1) may in general be prepared for example by oxidation of the corresponding nitrogen base as described above in relation to the preparation of intermediates of formula (5).

25

Salts of compounds of formula (1) may be prepared by reaction of compounds of formula (1) with an appropriate base in a suitable solvent or mixture of solvents e.g. an organic solvent such as an ether e.g. diethylether, or an alcohol, e.g. ethanol using conventional procedures.

30

Where it is desired to obtain a particular enantiomer of a compound of formula (1) this may be produced from a corresponding mixture of enantiomers using any suitable conventional procedure for resolving enantiomers.

5

Thus for example diastereomeric derivatives, e.g. salts, may be produced by reaction of a mixture of enantiomers of formula (1) e.g. a racemate, and an appropriate chiral compound, e.g. a chiral base. The diastereomers may then be separated by any convenient means, for example by crystallisation and the desired enantiomer recovered, e.g. by treatment with an acid in the instance where the diastereomer is a salt.

15 In another resolution process a racemate of formula (1) may be separated using chiral High Performance Liquid Chromatography. Alternatively, if desired a particular enantiomer may be obtained by using an appropriate chiral intermediate in one of the processes described above. Alternatively, a particular enantiomer may be obtained by performing an enantiomer specific enzymatic biotransformation e.g. an ester hydrolysis using an esterase and then purifying only the enantiomerically pure hydrolysed acid from the unreacted ester antipode.

20

Chromatography, recrystallisation and other conventional separation procedures may also be used with intermediates or final products where it is desired to obtain a particular geometric isomer of the invention.

25

The following Examples illustrate the invention. All temperatures are in °C. The following abbreviations are used:

NMM - N-methylmorpholine;	EtOAc - ethyl acetate;
MeOH - methanol;	BOC - butoxycarbonyl;
30 DCM - dichloromethane;	AcOH - acetic acid;
DIPEA - diisopropylethylamine;	EtOH - ethanol;

- Pyr - pyridine; Ar - aryl;
 DMSO - dimethylsulphoxide; iPr - isopropyl;
 Et₂O - diethylether; Me - methyl;
 THF - tetrahydrofuran; h – hour;
- 5 MCPBA - 3-chloroperoxybenzoic acid; NBS - N-bromosuccinimide;
 Fmoc - 9-fluorenylmethoxycarbonyl; r.t. – room temperature;
 DBU - 1,8-Diazabicyclo[5,4-0]undec-7-ene;
 EDC - 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride;
 HOBT - 1-hydroxybenzotriazole hydrate;
- 10 BINAP - 2,2'-bis(diphenylphosphino)-1-1'-binaphthyl;
 DMF - N,N-dimethylformamide;
 DME - Ethylene glycol dimethyl ether
 p.s.i. - pounds per square inch
 MTBE – methyl *tert*-butylether
- 15 m.p. – melting point

All NMRs were obtained either at 300MHz or 400MHz.

- 20 Compounds were named with the aid of either Beilstein Autonom supplied by MDL Information Systems GmbH, Theodor-Heuss-Allee 108, D-60486 Frankfurt, Germany or ACD Labs Name (v.6.0) supplied by Advanced Chemical Development, Toronto, Canada.
- 25 LCMS retention times (RT) quoted were generated on a Hewlett Packard 1100 LC/MS using the following following method: Phenomenex Luna 3 μ C₁₈(2) 50x4.6mm column; mobile phase A = 0.1% formic acid in water; mobile phase B = 0.1% formic acid in MeCN; flow rate of 0.9mLmin⁻¹, column temperature 40°C.

30

Gradient:-

Time (minutes)	%B	%A
Initial	5	95
2.0	95	5
3.0	95	5
5.0	5	95
5.5	end	end

Where stated alternative LCMS conditions (Conditions B) were used:

LCMS retention times (RT) quoted were generated on a Hewlett Packard
 5 1100/ThermoFinnigan LCQ Duo LC/MS system using Electrospray ionisation
 and the following LC method: Phenomenex Luna C₁₈(2) 5 μ 100mm x 4.6mm
 column; mobile phase A = 0.08% formic acid in water; mobile phase B =
 0.08% formic acid in MeCN; flow rate of 3.0 mLmin⁻¹, column temperature
 35°C.

10

Gradient:-

Time (min)	%A	%B
0.00	95.0	5.0
4.40	5.0	95.0
5.30	5.0	95.0
5.32	95.0	5.0
6.50	95.0	5.0

Intermediate 1

15 Ethyl 3-aminothieno[2,3-*b*]pyridine-2-carboxylate

A mixture of 2-chloro-3-cyanopyridine (330g, 2.3mol), ethyl 2-
 mercaptoacetate (361.2g, 3.0mol), sodium carbonate (265g, 2.5mol) and

EtOH (1.2L) was heated to reflux for 4.5 hours. The reaction mixture was cooled to ambient temperature and added to water (15L). The resultant precipitate was stirred for 30 minutes and then filtered. The filter cake was washed with two portions of water (2 x 2.5L) and dried to constant weight under vacuum at 45°C to yield the title compound as a brown solid (493.1g, 93.2%). δ H (CDCl₃) 8.68 (1H, dd, \underline{J} 4.7, 1.2Hz), 7.93 (1H, dd, \underline{J} 8.5, 1.2Hz), 7.29 (1H, dd, \underline{J} 8.5, 4.7Hz), 5.90 (2H, b), 4.38 (2H, q, \underline{J} 7.0Hz), 1.40 (3H, t, \underline{J} 7.0Hz). LCMS RT 2.9 minutes, 223 (M+H)⁺

10 **Intermediate 2**

Ethyl 3-bromothieno[2,3-*b*]pyridine-2-carboxylate

Intermediate 1 (363.6g) was added in portions over two hours to a mixture of copper(II) bromide (403.3g), t-butyl nitrite (220.6g) and acetonitrile (3.6L) stirred at a temperature of 20 to 25°C. The mixture was stirred at 20°C for 2 hours before it was slowly added to 2M HCl(aq) (4.2L). The reaction mixture slurry was filtered and the solids were washed with water (500mL). The combined filtrate was extracted with ethyl acetate (8L), this ethyl acetate solution was washed with 2M HCl(aq) (2.2L). The solids were dissolved in ethyl acetate (6L), this solution was washed twice with 2M HCl(aq) (4.4L and 2.2L). The two ethyl acetate solutions were then combined and washed with 2M HCl(aq) (2.2L) and twice with water (2 x 2L). The ethyl acetate solution was then dried (MgSO₄), filtered and concentrated *in vacuo* at 40 mbar and 60°C to give a solid residue. This was broken up and dried to constant weight under vacuum at 45°C to yield the title compound as a brown solid (458.5g, 97.9%). δ H (DMSO-d₆) 8.89 (1H, d, \underline{J} 4.7Hz), 8.47 (1H, d, \underline{J} 8.6Hz), 7.71 (1H, dd, \underline{J} 8.6, 4.7Hz), 4.46 (2H, q, \underline{J} 7.2Hz), 1.40 (3H, t, \underline{J} 7.2Hz). LCMS RT 3.8 minutes, 288 (M+H)⁺

Intermediate 3

Ethyl 3-Bromothieno[2,3-b]pyridine-2-carboxylate N-oxide

To a slurry of Intermediate 2 (214g, 0.747mol) in DCM (2140mL) under
5 nitrogen was added 70% mCPBA (240g, 0.97mol) portion wise over 0.5h.
The reaction was then stirred at room temperature for 18h. The reaction
mixture was quenched with water (800mL) and pH adjusted to 8.5 with
10%w/v sodium carbonate solution (1250mL). The basic aqueous layer was
10 removed and the organic layer washed with water until pH 7. The organic
layer was concentrated *in vacuo* and the crude title product was recovered as
a tan solid. The crude product was purified by slurrying in MTBE (600mL) for
1h at 0-5°C to give the title compound (174g, 77%). δ H (CDCl₃) 8.44 (1H, dd,
 \downarrow 6.2, 0.8Hz), 7.87 (1H, dd, \downarrow 8.3, 0.8Hz), 7.48 (1H, dd, \downarrow 8.3, 6.2Hz), 4.49
(2H, q, \downarrow 7.1Hz), 1.48 (3H, t, \downarrow 7.1Hz). LCMS (ES⁺) RT 2.61 minutes, 302
15 (M+H)⁺.

Intermediate 4

Ethyl 3-bromo-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate

20 To a suspension of Intermediate 3 (95g, 0.32mol) in DMF (950mL) and
stirred at room temperature was added trifluoroacetic anhydride (198g,
131mL, 0.94mol) dropwise over a 30 minute period (slight exotherm
observed). After complete addition the reaction was stirred for a further 45
minutes at room temperature. The excess trifluoroacetic anhydride was
25 removed under vacuum and the reaction mixture concentrated to
approximately half the original volume. The resulting dark coloured solution
was then poured onto a mixture of water (1L) toluene (400mL). The mixture
was left to stand for around 10 minutes and then the precipitate was collected
by filtration. The precipitate was washed with toluene (3 X 50mL) and then
30 dried in a vacuum oven at 50-60°C. This gave the title compound as a beige

coloured solid (68.5g, 72.1%). δ H (DMSO-d₆) 12.20 (1H, brs), 7.75 (1H, d, \downarrow 9.0Hz), 6.50 (1H, d, \downarrow 9.0Hz), 4.15 (2H, q, \downarrow 7.1Hz), 1.12 (3H, t, \downarrow 7.1Hz). LCMS (ES⁺) RT 2.86 minutes, 302 (M+H)⁺. m.p. 261.7-268.1°C.

5 Intermediate 5 (Method A)

Ethyl 3-bromo-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate

A 3L jacketed vessel was charged with Intermediate 4 (100g, 0.332mol), CuI (15.8g, 0.083mol), phenylboronic acid (80g, 0.664mol), pyridine (104g, 1.32mol) and acetonitrile (2.0L) and the mixture stirred at 40°C. Compressed air was vigorously blown through the reaction mixture for 6 hours. The compressed air was then turned off and the reaction mixture left to stir at 40°C overnight. The next day the same process was repeated. After approximately 36 hours, HPLC indicated >97% conversion of starting material to the product. The resulting dark coloured reaction mixture was poured onto a mixture of water (1.2L) and concentrated hydrochloric acid (300mL). The mixture was extracted with dichloromethane (2 X 1.5L) and the combined organics washed with 2M HCl(aq) (2 x 1.5L). The organic layer was separated, passed through a pad of MgSO₄, and concentrated *in vacuo*. The crude residue was recrystallised from toluene (600ml) to give the title compound as a beige solid (93.85g, 75.0%). δ H (CDCl₃) 7.82 (1H, d, \downarrow 8.5Hz), 7.70-7.62 (3H, m), 7.54-7.42 (2H, m), 6.70 (1H, d, \downarrow 8.5Hz), 4.15 (2H, q, \downarrow 7.1Hz), 1.14 (3H, t, \downarrow 7.1Hz). LCMS (ES⁺) RT 3.75 minutes, 378 (M+H)⁺. MP = 201.6-206.0°C

25

Intermediate 5 (alternative procedure Method B)

Ethyl 3-bromo-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate

To a 2 necked round bottomed flask was added in sequence Intermediate 4 (302mg, 1.00mmol), copper(II) acetate (278mg, 1.50mmol), phenylboronic acid (488mg, 4.00mmol), DCM (5mL) and pyridine (158mg, 2.00mmol). The

reaction was stirred at room temperature for 18h with the exclusion of moisture. The reaction was then diluted with DCM (50mL), washed with 2M HCl(aq) (50mL), the aqueous was re-extracted with DCM (50mL). The combined organics were then washed with water (50mL), dried (MgSO₄) and concentrated *in vacuo*. The crude product was purified by a slurry in methanol (12mL), to give the title compound as a beige solid (270mg, 72%). δ H (CDCl₃) 7.82 (1H, d, \underline{J} 8.5Hz), 7.70-7.62 (3H, m), 7.54-7.42 (2H, m), 6.70 (1H, d, \underline{J} 8.5Hz), 4.15 (2H, q, \underline{J} 7.1Hz), 1.14 (3H, t, \underline{J} 7.1Hz). LCMS (ES⁺) RT 3.75 minutes, 378 (M+H)⁺.

Intermediate 6

Ethyl 3-bromo-7-(4-methylphenyl)-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate

A flask was charged with Intermediate 4 (15.1g, 0.05mol), copper (II) acetate (13.62g, 0.075mol), 4-tolylboronic acid (14.0g, 0.1mol), DCM (500mL) and pyridine (25mL, 0.3mol) and the mixture stirred at r.t. for 24h. The reaction mixture was washed with 2M HCl (2 x 200mL), 5% NaOH (aq) (200mL), brine (200mL) and dried (MgSO₄). Solvent was removed *in vacuo* and the resultant solid triturated with methanol to give the title compound as a solid (15.7g). δ H (CDCl₃) 7.76 (1H, d, \underline{J} 9.7Hz), 7.33 (2H, d, \underline{J} 8.3Hz), 7.18 (2H, d, \underline{J} 8.3Hz), 6.64 (1H, d, \underline{J} 9.7Hz), 4.24 (2H, q, \underline{J} 7.1Hz), 2.39 (3H, s), 1.26 (3H, t, \underline{J} 7.1Hz). LCMS (ES⁺) RT 3.86 minutes, 394 (M+H)⁺.

Intermediate 7

Ethyl 3-bromo-7-(4-fluorophenyl)-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate

From Intermediate 4 and 4-fluorophenylboronic acid by the method of Intermediate 6. White solid. δ H (CDCl₃) 7.84 (1H, d, \underline{J} 9.7Hz), 7.41-7.37 (2H, m), 7.32-7.25 (2H, m), 6.72 (1H, d, \underline{J} 9.7Hz), 4.33 (2H, q, \underline{J} 7.1Hz), 1.34 (3H, t, \underline{J} 7.1Hz). LCMS (ES⁺) RT 3.729 minutes, 397.8 (M+H)⁺.

Intermediate 8

Ethyl 3-bromo-7-(4-chlorophenyl)-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate

From Intermediate 4 and 4-chlorophenylboronic acid by the method of
5 Intermediate 6. δ H (CDCl₃) 7.86 (1H, d, *J* 9.6Hz), 7.60 (2H, d, *J* 8.5Hz), 7.37 (2H, d, *J* 8.5Hz), 6.74 (1H, d, *J* 9.6Hz), 4.35 (2H, q, *J* 7.1Hz), 1.36 (3H, t, *J* 7.1Hz). LCMS (ES⁺) RT 3.937 minutes, 413 (M+H)⁺.

Intermediate 9

Ethyl 3-bromo-7-(3-methylphenyl)-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate

From Intermediate 4 and 3-methylphenylboronic acid by the method of
Intermediate 6. δ H (CDCl₃) 7.85 (1H, d, *J* 9.6Hz), 7.51-7.48 (1H, m), 7.38-
7.27 (1H, m), 7.29 (2H, br m), 6.75 (1H, d, *J* 9.6Hz), 4.34 (2H, q, *J* 7.1Hz),
15 2.46 (3H, s), 1.35 (3H, t, *J* 7.1Hz). LCMS (ES⁺) RT 3.865 minutes, 393 (M+H)⁺.

Intermediate 11

Ethyl 3-bromo-7-(cyclopropylmethyl)-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate

Sodium hydride (60% in mineral oil)(3.27g, 81.4mmol) was added in portions
to a solution of Intermediate 4 (22.3g, 74mmol) in DMF (300mL) at 0 °C. The
mixture was stirred at r.t. for 30min then cyclopropylmethyl bromide (10g,
74mmol) was added slowly and the mixture heated at 60 °C overnight. The
25 DMF was removed *in vacuo* and the residue partitioned between EtOAc and
brine. The organic phase was dried (MgSO₄) and concentrated *in vacuo*.
Purification by column chromatography (silica, 0% to 10% EtOAc in DCM)
gave the title compound as a yellow solid (12.5g, 47%). δ H (CDCl₃) 7.57 (1H,
d, *J* 9.5Hz), 6.47 (1H, d, *J* 9.5Hz), 4.22 (2H, q, *J* 7.0Hz), 3.87 (2H, d, *J*
30 7.1Hz), 1.26-1.19 (4H, m), 0.43-0.37 (4H, m). LCMS (ES⁺) RT 3.80 minutes,
357 (M+H)⁺.

Intermediate 12

Ethyl 3-[(4-fluoro-3-methylphenyl)amino]-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate

The intermediate 5 (1.00g, 2.64mmol), tris(dibenzylideneacetone) dipalladium(0) (0.121g, 0.132mmol) and BINAP (0.164g, 0.264mmol) were stirred in toluene (12mL) for 5 mins. 4-Fluoro-3-methylaniline (0.397g, 3.172mmol) and cesium carbonate (1.205g, 3.701mmol) were added and the mixture was heated at reflux under N₂ for 24 hr. The mixture was dissolved in THF (100mL) and washed with water. The combined organics were dried (Na₂SO₄) and concentrated *in vacuo*. The residue was triturated with MeOH to produce the title compound as a white solid (0.754g). δ H (DMSO-d₆) 8.72 (1H, s), 7.67-7.60 (3H, m), 7.51-7.49 (2H, m), 7.18-7.10 (3H, m), 7.09-6.99 (1H, m), 6.39 (1H, d, *J* 9.7 Hz), 4.15 (2H, q, *J* 7.07 Hz), 2.22 (3H, s), 1.72 (3H, t, *J* 7.08 Hz). LCMS (ES⁺) 423 (M+H)⁺.

15

Intermediate 13

Ethyl 3-[(2,4-difluorophenyl)amino]-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate

Tris(dibenzylideneacetone)dipalladium(0) (1.21g, 1.32mmol) was added to a mixture of Intermediate 5 (10g, 26.4mmol), caesium carbonate (12.05g, 37.0mmol), 2,4-difluoroaniline (4.1g, 3.23mL, 31.7mmol) and BINAP (1.65g, 2.64mmol) in anhydrous toluene (80mL) and the reaction heated to reflux under nitrogen for 4 days. The reaction was cooled, partitioned between DCM and water and the organic phase dried (MgSO₄) and evaporated *in vacuo*. The crude residue was triturated with methanol to give the title compound as a white solid (9.87g) δ H (CDCl₃) 8.49 (1H, bs), 7.58-7.40 (3H, m), 7.32-7.25 (2H, m), 7.13-7.04(1H, m), 7.01 (1H, d, *J* 9.8Hz), 6.93-6.86 (1H, m), 6.82-6.75 (1H, m), 6.31 (1H, d, *J* 9.8Hz), 4.20 (2H, q, *J* 7.1Hz), 1.23 (3H, *J* 7.1Hz). LCMS (ES⁺) RT 4.06 minutes, 427 (M+H)⁺.

30

General procedure for the preparation of Ethyl 3-anilino-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate intermediates

The Intermediate esters 14-26 were prepared following a procedure similar to that described for Intermediate 13. Therefore to an oven dried reaction flask
5 was added a magnetic stirrer, the appropriate substituted aniline (1.2 equiv.), anhydrous toluene, Intermediate 5 (1.0 equiv.), caesium carbonate (1.4equiv.), tris(dibenzylideneacetone)dipalladium(0) (5mol%) and BINAP (10mol%). The reactions were heated to reflux under nitrogen and with magnetic stirring for 24-48h. Each reaction was then diluted with DCM,
10 washed with water, dried (MgSO₄) and concentrated *in vacuo*. The crude products were either purified on silica eluting with a gradient of EtOAc in DCM or alternatively by trituration with methanol or ethyl acetate to give the title compounds as solids.

15 **Intermediate 14**

Ethyl 3-anilino-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate

From Intermediate 5 and aniline to give the title compound as a white solid. δ H (CDCl₃) 8.70 (1H, bs), 7.57-7.47 (3H, m), 7.33-7.25 (4H, m), 7.20-
20 7.10 (4H, m), 6.27 (1H, d, \downarrow 9.7Hz), 4.19 (2H, q, \downarrow 7.1Hz), 1.22 (3H, t, \downarrow 7.1Hz). LCMS (ES⁺) RT 4.10 minutes, 391 (M+H)⁺.

Intermediate 15

25 **Ethyl 3-[(2-chlorophenyl)amino]-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate**

From 2-chloroaniline and Intermediate 5 to give the title compound as a solid. δ H (CDCl₃) 8.60 (1H, bs), 7.56-7.48 (3H, m), 7.40-7.38 (1H, m), 7.36-7.32 (2H, m), 7.20-7.15 (2H, m), 7.14-7.05 (1H, m), 7.05-6.98(1H, m), 6.35 (1H, d, \downarrow 9.8Hz), 4.21 (2H q, \downarrow 7.1Hz), 1.23 (3H, t, \downarrow 7.1Hz). LCMS (ES⁺) RT 4.38
30 minutes, 425 (M+H)⁺.

Intermediate 16

Ethyl 3-[(3-cyanophenyl)amino]-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate

From 3-cyanoaniline and Intermediate 5 to give the title compound an off-white solid. δ H (CDCl₃) 8.58 (1H, bs), 7.61-7.43 (3H, m), 7.40-7.20 (6H, m), 7.14 (1H, d, \underline{J} 9.8Hz), 6.38 (1H, d, \underline{J} 9.8Hz), 4.19 (2H, q, \underline{J} 7.1Hz), 1.23 (3H, t, \underline{J} 7.1Hz). LCMS (ES⁺) RT 3.78 minutes, 416 (M+H)⁺.

Intermediate 17

10 **Ethyl 3-[(2-cyanophenyl)amino]-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate**

From 2-cyanoaniline and Intermediate 5 to give the title compound. δ H (CDCl₃) 8.72 (1H, bs), 7.61-7.47 (4H, m), 7.43-7.40 (1H, m), 7.36-7.31 (2H, m), 7.22-7.15 (1H, m), 7.11-7.00 (2H, m), 6.40 (1H, d, \underline{J} 9.8Hz), 4.22 (2H, q, \underline{J} 7.1Hz), 1.24 (3H, t, \underline{J} 7.1Hz). LCMS (ES⁺) RT 3.80 minutes, 416 (M+H)⁺.

Intermediate 20

Ethyl 3-[(3-chloro-4-fluorophenyl)amino]-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate

20 From Intermediate 5 and 3-chloro-4-fluoroaniline to give the title compound as a solid. δ H (CDCl₃) 8.70 (1H, s), 7.67-7.59 (3H, m), 7.44-7.41 (2H, m), 7.24-7.02 (4H, m), 6.43 (1H, d, \underline{J} 9.8Hz), 4.28 (2H, q, \underline{J} 7.1Hz), 1.31 (3H, t, \underline{J} 7.1Hz). LCMS (ES⁺) RT 4.245 minutes, 443 (M+H)⁺.

25 **Intermediate 21**

Ethyl 3-[(4-fluoro-3-methylphenyl)amino]-7-(4-fluorophenyl)-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate

From Intermediate 7 and 4-fluoro-3-methylaniline to give the title compound. Light yellow solid. δ H (CDCl₃) 8.78 (1H, br s), 7.38-7.35 (2H, m), 7.28-7.24

(2H, m), 7.04-6.96 (4H, m), 6.3 (1H, d, *J* 9.8Hz), 4.24 (2H, q, *J* 7.1Hz), 2.25 (3H, s), 1.28 (3H, t, *J* 7.1Hz). LCMS (ES⁺) RT 4.298 minutes, 441.0 (M+H)⁺.

Intermediate 22

5 **Ethyl 3-[(4-fluoro-3-methylphenyl)amino]-7-(4-chlorophenyl)-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate**

From Intermediate 8 and 4-fluoro-3-methylaniline to give the title compound as a solid. δ H (CDCl₃) 8.72 (1H, br s), 7.58-7.38 (2H, m), 7.35-7.28 (2H, m), 6.99-6.98 (4H, m), 6.34 (1H, d, *J* 9.8Hz), 4.28 (2H, q, *J* 7.1Hz), 2.29 (3H, s),
10 1.32 (3H, t, *J* 7.1Hz). LCMS (ES⁺) RT 4.57 minutes, 457 (M+H)⁺.

Intermediate 23

Ethyl 3-[(4-fluoro-3-methylphenyl)amino]-7-(3-methylphenyl)-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate

15 From Intermediate 9 and 4-fluoro-3-methylaniline to give the title compound as a solid. δ H (CDCl₃) 8.63 (1H, br s), 7.4-7.15 (1H, m), 7.30-7.27 (1H, m), 7.18-7.10 (2H, m), 7.04-6.90 (4H, m), 6.27 (1H, d, *J* 9.7Hz), 4.18 (2H, q, *J* 7.1Hz), 2.21 (3H, s), 2.20 (3H, s), 1.21 (3H, t, *J* 7.1Hz). LCMS (ES⁺) RT 4.469 minutes, 437 (M+H)⁺.

20

Intermediate 24

Ethyl 3-[(3-methylphenyl)amino]-7-(3-methylphenyl)-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate

From Intermediate 9 and 3-methylaniline to give the title compound as a
25 solid. δ H (CDCl₃) 8.55 (1H, br s), 7.32-7.28 (1H, m), 7.27-7.17 (1H, m), 7.08-7.00 (4H, m), 7.88-7.75 (3H, m), 6.15 (1H, d, *J* 9.8Hz), 4.08 (2H, q, *J* 7.1Hz), 2.27 (3H, s), 2.17 (3H, s), 1.12 (3H, t, *J* 7.1Hz). LCMS (ES⁺) RT 4.543 minutes, 419 (M+H)⁺.

30 **Intermediate 25**

Ethyl 3-anilino-7-[4-(dimethylamino)phenyl]-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate

From Intermediate 10 and aniline to give the title compound as a solid. δ H (CDCl₃) 8.69 (1H, br s), 7.26 (2H, t, *J* 8.0Hz), 7.14 (2H, d, *J* 9.0Hz), 7.10-7.05 (4H, m), 6.75 (2H, d, *J* 9.0Hz), 6.26 (1H, d, *J* 9.7Hz), 4.17 (2H, q, *J* 7.1Hz), 2.96 (6H, s), 1.21 (3H, t, *J* 7.1Hz). LCMS (ES⁺) RT 4.31 minutes, 434 (M+H)⁺.

Intermediate 26

10 **Ethyl 3-anilino-7-(cyclopropylmethyl)-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate**

From Intermediate 11 and aniline to give the title compound. Pale yellow solid. δ H (CDCl₃) 8.71 (1H, br s), 7.29-7.22 (2H, m), 7.10-6.97 (4H, m), 6.18 (1H, d, *J* 9.7Hz), 4.27 (2H, q, *J* 7.1Hz), 3.94 (2H, d, *J* 7.2Hz), 1.40-1.33 (1H, m), 1.32 (3H, t, *J* 7.1Hz), 0.53-0.48 (4H, m). LCMS (ES⁺) RT 3.79 minutes, 369.0 (M+H)⁺.

Intermediate 27

20 **Lithium 3-[(4-fluoro-3-methylphenyl)amino]-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate**

Intermediate 12 (0.494g, 1.170mmol) was dissolved in EtOH/THF/H₂O (2:1:1) (20mL), heated to 80 °C and treated with LiOH.H₂O (0.054g, 1.287mmol). Reaction was continued until no starting material remained (as judged by TLC). The solvent was removed *in vacuo* and the residue azeotroped with toluene to give the title compound as a beige solid (0.284g). δ H (DMSO-d₆) 7.81-7.75 (3H, m), 7.64-7.62 (2H, m), 7.41-7.38 (1H, d, *J* 9.55 Hz), 7.20-7.15 (1H, t, *J* 9.01 Hz), 7.04-7.03 (1H, br m), 6.93-6.90 (1H, br m), 6.48-6.46 (1H, d, *J* 9.54 Hz), 2.35 (3H, s). LCMS (ES⁺) 395 (M+H)⁺.

30 **Intermediate 28**

Lithium 3-[(2,4-difluorophenyl)amino]-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate

The title compound was prepared from Intermediate 13 (6.34g, 14.9mmol) and lithium hydroxide monohydrate (686mg, 16.4mmol) following the method of intermediate 27. δ H (DMSO- d_6) 10.04 (1H, bs), 7.81 (3H, m), 7.69 (2H, m), 7.50 (1H, m), 7.48 (1H, d, J 9.6Hz), 7.16 (2H, m), 7.56 (1H, d, J 9.6Hz).

Intermediate 29

Ammonium 6-Oxo-3-(phenylamino)-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate

A solution of sodium hydroxide (339mg, 8.5mmol, 1.1equiv.) in water (20mL) was added to a suspension of Intermediate 14 (3.0g, 7.7mmol, 1.0equiv.) in ethanol (50mL) and the mixture heated at reflux for 2h. The bulk of the ethanol was removed *in vacuo* and the residue treated with sat. ammonium chloride solution(aq) (30mL). The resultant solid was collected by filtration, washed with water (2 x 20mL), Et₂O (2 x 20mL) and dried *in vacuo* at room temperature to give the title compound as a white solid in quantitative yield. δ H (DMSO- d_6) 9.60 (1H, bs), 7.65-7.57 (3H, m), 7.49-7.46 (2H, m), 7.29-7.18 (3H, m), 6.97-6.91 (3H, m), 6.34 (1H, d, J 9.6Hz). LCMS (ES⁺) RT 3.24 minutes, 363 (M+H)⁺.

Intermediate 30

Sodium 6-oxo-7-(4-chlorophenyl)-3-[(4-fluoro-3-methylphenyl)amino]-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate

The title compound was prepared from Intermediate 22 (1.0g, 2.1mmol) and sodium hydroxide (100mg, 2.6mmol, 1.2equiv.) following a procedure analogous to that used for Intermediate 29. Instead of treating with a saturated ammonium chloride solution the volatiles were removed *in vacuo* and the residue triturated with EtOAc to give the title compound as a solid (800mg). δ H (DMSO- d_6) 9.74 (1H, bs), 7.67 (2H, dd, J 6.6, 2.1Hz), 7.54 (2H, dd, J 6.6, 2.1Hz), 7.24 (1H, d, J 9.6Hz), 7.20-7.01 (1H, m), 6.90-6.80 (1H, m),

6.85-6.75 (1H, m), 6.31 (1H, d, Δ 9.5Hz), 4.68 (3H, s). LCMS (ES⁺) RT 3.51 minutes, 429 (M+H)⁺.

Intermediate 31

5 **Sodium 6-Oxo-3-[(4-fluoro-3-methylphenyl)amino]-7-(3-methylphenyl)-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate**

The title compound was prepared from Intermediate 23 (1.0g, 2.2mmol) and sodium hydroxide (183mg, 4.4mmol) following the procedure of Intermediate 30 to give the title compound as a solid (1.0g). δ H (DMSO-d₆) 7.56 (1H, t, Δ 7.7Hz), 7.44 (1H, d, Δ 7.7Hz), 7.38-7.24 (3H, m), 7.07 (1H, t, Δ 9.1Hz), 6.96-6.91 (1H, m), 6.88-6.75 (1H, m), 6.37 (1H, d, Δ 9.6Hz), 2.47 (3H,s), 2.25 (3H, s).

Intermediate 32


15 **Sodium 6-oxo-3-[(3-methylphenyl)amino]-7-(3-methylphenyl)-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate**

The title compound was prepared from Intermediate 24 (1.0g, 2.3mmol) and sodium hydroxide (140mg, 3.5mmol) following the procedure of Intermediate 30 to give the title compound as a solid (842mg). δ H (DMSO-d₆) 9.81 (1H, bs), 7.55 (1H, t, Δ 7.6Hz), 7.47 (1H, d, Δ 12 Hz), 7.42-7.24 (3H, m), 7.18 (1H, t, Δ 7.7Hz), 6.80-6.75 (3H, m), 6.37 (1H, Δ 9.5 Hz), 2.46 (3H, s), 2.31 (3H, s).

Intermediate 33

25 **Sodium 3-[(3-Chloro-4-fluorophenyl)amino]-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate**

The title compound was prepared from Intermediate 20 (1.0g, 2.2mmol) and sodium hydroxide (100mg, 2.69mmol) following the procedure of Intermediate 30 to give the title compound as a solid (680mg). δ H (DMSO-d₆) 9.78 (1H, bs), 7.61-7.59 (3H, m), 7.55-7.46 (2H, m), 7.30-7.24 (2H, m), 7.09-7.06 (1H, m), 6.90-6.88 (1H, m), 6.34(1H, d, Δ 9.4 Hz). LCMS (ES⁺) RT 3.41 minutes, 414 (M+H)⁺.



Intermediate 34

5 Pentafluorophenyl 3-[(4-fluoro-3-methylphenyl)amino]-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate

EDC (0.163g, 0.852mmol) was added to a solution of Intermediate 27 (0.284g, 0.710mmol) in DMF (10mL) and the mixture stirred at r.t. for 30 min. Pentafluorophenol (0.196g, 1.065mmol) was added and the mixture stirred at
 10 r.t. for 24hr. The solvent was removed *in vacuo* and the residue was dissolved in DCM which was then washed with water, dried (MgSO₄) and concentrated *in vacuo*. Purification by column chromatography (silica, 50 % Hexane/ EtOAc) to produce the title compound as a white solid (0.226g). δ H (DMSO-d₆) 8.96 (1H, s), 7.07-6.95 (5H, br m), 7.55-7.39 (4H, br m), 6.29
 15 (1H, d, *J* 9.86 Hz), 2.08 (3H, s). LCMS (ES⁺) 561 (M+H)⁺.

Intermediate 35

Pentafluorophenyl 3-[(2,4-difluorophenyl)amino]-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate

20 The title compound was prepared from Intermediate 28 following the method of Intermediate 34 to give the product as a white solid. δ H (CDCl₃) 8.66 (1H, bs), 7.76 (3H, m), 7.58 (2H, m), 7.47 (1H, m), 7.14 (3H, m), 6.54 (1H, d, *J* 9.9Hz). LCMS (ES⁺) RT 4.57 minutes, 565 (M+H)⁺.

25

Intermediate 36

3-Bromo-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylic acid

Sodium hydroxide (1.83g, 45.8mmol, 1.1equiv.) was added to a suspension of Intermediate 5 (15.75g, 41.6mmol, 1.0equiv.) in ethanol (78mL) and water (78ml) at room temperature. The reaction mixture was then heated to reflux. Once reflux was attained the solid material had gone into solution and analysis by HPLC indicated complete conversion to the acid. The reaction mixture was then cooled to ~70°C and c.hydrochloric acid (46ml) added over a 10 minute period. The reaction was allowed to cool to room temperature and the resultant solid collected by filtration, washed with water (3 x 25ml) and dried *in vacuo* to give the title compound as a beige solid (13.81g, 97%).
5
10 δ H (DMSO-d6) 8.13 (1H, d, \underline{J} 9.6Hz), 7.92-7.80 (3H, m), 7.78-7.74 (2H, m), 6.92 (1H, d, \underline{J} 9.6Hz).

Intermediate 37

3-Bromo-7-(4-methylphenyl)-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylic acid
15
The title compound was prepared from Intermediate 6 (16.0g, 40.3mmol) following the method of Intermediate 36 to give the product as a solid (13.84g). δ H (DMSO-d6) 7.85 (1H, d, \underline{J} 9.6Hz), 7.45-7.38 (4H, m), 6.65 (1H, d, \underline{J} 9.6Hz), 2.42 (3H, s).
20

Intermediate 38

3-Bromo-7-(4-fluorophenyl)-6-oxo -6,7-dihydrothieno[2,3-b]pyridine-2-carboxylic acid
A solution of lithium hydroxide monohydrate (0.87g, 20.8mmol) in water (30mL) was added to a solution of Intermediate 7 (5.5g, 13.9mmol) in dioxane (100mL) and the reaction stirred at r.t. for 4h. Concentrated hydrochloric acid was added dropwise until the product had precipitated. The resultant solid was collected by filtration, washed with water (2 x 30mL), diethyl ether (2 x 30mL) and dried in a vacuum oven to give the title compound as a solid (4.65g, 91%). δ H (DMSO-d6) 7.66 (1H, d, \underline{J} 9.6Hz), 7.43-7.38 (2H, m), 7.30-7.24 (2H, m), 6.46 (1H, d, \underline{J} 9.6Hz).
25
30

Intermediate 39

3-Bromo-2-([(2*R*)-2-(hydroxymethyl)pyrrolidin-1-yl]carbonyl)-7-phenylthieno[2.3-*b*]pyridin-6(7*H*)-one

To a solution of Intermediate 36 (10.0g, 28.6mmol) and DMF (2 drops) in
5 THF (150mL) was added oxalyl chloride (3.26mL, 37.4mmol), via syringe,
over a 30 minute period. The reaction mixture was stirred for a further 30
minutes at room temperature before removing solvent and excess reagent *in*
vacuo to give the intermediate acid chloride as a beige solid. This acid
chloride was dissolved in DCM (150mL) and added over 45 minutes to a
10 mixture of (*R*)-2-pyrrolidinemethanol (2.88g, 28.5mmol) and triethylamine
(4.36mL, 31.3mmol) in 100mL of dichloromethane. After complete addition
the reaction was stirred for 1h at ambient temperature. The reaction mixture
was poured onto water (200mL), the DCM layer separated and the aqueous
re-extracted with DCM (100mL). The combined organic layers were then
15 washed with water (200mL), dried (MgSO₄) and evaporated to give the title
compound as a light brown solid (12.83g). δ H (CDCl₃) 7.70 (1H, d, \underline{J} 9.6Hz),
7.50-7.60 (3H, m), 7.35-7.45 (2H, m), 6.75 (1H, d, \underline{J} 9.6Hz), 4.25-4.35 (1H,
m), 4.00 (1H, BrS), 3.45-3.80 (4H, m), 1.52-2.55 (4H, m). LCMS (ES⁺) RT
2.52 minutes, 433.1 (M+H)⁺.

20

Intermediate 40

3-Bromo-2-([(2*R*)-2-(hydroxymethyl)pyrrolidin-1-yl]carbonyl)-7-(4-methylphenyl)thieno[2.3-*b*]pyridin-6(7*H*)-one

To a suspension of Intermediate 37 (6.4g, 17.5mmol) in DCM (80mL) was
25 added EDC (5.04g, 26mmol) and the reaction stirred at r.t. for 1h. (*R*)-2-
pyrrolidinemethanol (2.6mL, 26mmol) was added and the reaction stirred for
18h at room temperature. The reaction was diluted with DCM (10mL),
washed with brine, dried (MgSO₄) and concentrated *in vacuo*. The crude
residue was purified by chromatography (silica, 30-50%EtOAc in DCM) to
30 give the title compound as a white solid (3.44g, 43%). δ H (CDCl₃) 7.65 (1H,
d, \underline{J} 9.6Hz), 7.37 (2H, d, \underline{J} 8.2Hz), 7.20-7.19 (2H, m), 6.66 (1H, d, \underline{J} 9.6Hz),

4.25-4.23 (1H, m), 3.80-3.40 (4H, m), 2.37 (3H, s), 2.13-2.04 (1H, m), 1.79-1.53 (3H, m). LCMS (ES⁺) RT 2.92 minutes, 449 (M+H)⁺.

Intermediate 41

5 **3-Bromo-7-(4-fluorophenyl)-2-[(2R)-2-(hydroxymethyl)pyrrolidin-1-yl]carbonyl}thieno[2,3-b]pyridin-6(7H)-one**

The title compound was prepared from Intermediate 38 and (*R*)-2-pyrrolidinemethanol following the method described for Intermediate 40 to give the product as a solid. LCMS (ES⁺) RT 2.83 minutes, 452 (M+H)⁺.

10

Intermediate 42

3-Bromo-7-phenyl-2-[(2R)-2-[(tetrahydro-2H-pyran-2-yloxy)methyl]pyrrolidin-1-yl]carbonyl}thieno[2,3-b]pyridin-6(7H)-one

To a 1l round bottomed flask was added the Intermediate 39 (12.5g, 15 28.8mmol), dihydropyran (12.1g, 144.8mmol), *p*-toluenesulphonic acid (55mg, 0.29mmol) and dichloromethane (5000mL). The reaction mixture was then stirred at room temperature for 5 hours. The reaction mixture was poured onto water (200mL), saturated brine (100mL) and sodium bicarbonate solution (100mL). The layers were separated and the aqueous layer re- 20 extracted with dichloromethane (100mL). The combined organic layers were then washed with the above aqueous mixture, dried (MgSO₄) and evaporated to dryness. Purification by column chromatography (270g silica gel) eluting with ethyl acetate gave the title compound as a light brown solid/foam (12.73g). δH (DMSO-d₆) 7.80 (1H, d, \downarrow 9.6Hz), 7.70-7.45 (5H, m), 6.60 (1H, 25 d, \downarrow 9.6Hz), 4.50 (1H, m), 4.15 (1H, brs), 3.35-3.80 (6H, m), 1.30-2.00 (10H, m). LCMS (ES⁺) RT 3.65 minutes, 519.1 (M+H)⁺

Intermediate 43

30 **3-Bromo-7-(4-methylphenyl)-2-[(2R)-2-[(tetrahydro-2H-pyran-2-yloxy)methyl]pyrrolidin-1-yl]carbonyl}thieno[2,3-b]pyridin-6(7H)-one**

The title compound from Intermediate 40 (3.44g, 7.6mmol) following the procedure used for Intermediate 42. This gave the title compound as a light brown solid (4.85g). δ H (CDCl₃) 7.63 (1H, d, $\underline{\text{J}}$ 9.6Hz), 7.28 (2H, d, $\underline{\text{J}}$ 7.8Hz), 7.17 (2H, m), 6.63 (1H, d, $\underline{\text{J}}$ 9.6Hz), 4.48-4.28 (2H, m), 3.85-3.30 (6H, m), 2.36 (3H, s), 2.15-1.70 (7H, m), 1.48-1.46 (3H, m). LCMS (ES⁺) RT 3.69 minutes, 533 (M)⁺.

Intermediate 44

3-Bromo-7-(4-fluorophenyl)-2-((2R)-2-((tetrahydro-2H-pyran-2-yloxy)methyl)pyrrolidin-1-yl)carbonyl)thieno[2,3-b]pyridin-6(7H)-one

The title compound from Intermediate 41 (1.0g, 2.21mmol) following the procedure used for Intermediate 42. This gave the title compound as a light brown oil (0.95g). δ H (CDCl₃) 7.90 (1H, d, $\underline{\text{J}}$ 9.6Hz), 7.69 (2H, m), 7.56 (2H, t, $\underline{\text{J}}$ 8.7Hz), 6.73 (1H, d, $\underline{\text{J}}$ 9.6Hz), 4.61-4.57 (1H, m), 3.97-3.37 (8H, m), 1.97-1.50 (9H, m). LCMS (ES⁺) RT 3.51 minutes, 560 (M+Na)⁺.

Intermediate 45

3-((2,4-Difluorophenyl)amino)-7-phenyl-2-((2R)-2-((tetrahydro-2H-pyran-2-yloxy)methyl)pyrrolidin-1-yl)carbonyl)thieno[2,3-b]pyridin-6(7H)-one

To a dry 500ml 2 necked round bottomed flask, fitted with nitrogen inlet/outlet was added Cs₂CO₃ (11.2g, 31.7mmol), (+/-)-BINAP (1.53g, 2.46mmol), Intermediate 42 (12.73g, 24.6mmol) and Pd₂(dba)₃ (1.12g, 1.22mmol). To this mixture was added anhydrous toluene (200mL), which had been thoroughly degassed, and then 2,4-di-fluoroaniline (3.49g, 27.0mmol) and the reaction heated at reflux under nitrogen for 48h. The reaction mixture was cooled to ambient and then poured onto 1.0M HCl(aq) (300mL). This was extracted with dichloromethane (2 x 100mL) and the combined organics washed with 1.0M HCl(aq) (2 x 300mL), dried (MgSO₄) and concentrated *in vacuo* to give a brown oil. The crude product was purified by column chromatography (silica, 3:2 ethylacetate:heptane) to give the title compound as a light yellow solid (7.32g). δ H (DMSO-d₆) 8.75 (1H, s), 7.75 (1H, d, $\underline{\text{J}}$

8.3Hz), 7.70-7.60 (3H, m), 7.55-7.43 (2H, m), 7.35-7.22 (1H, m), 7.05-6.88 (2H, m), 6.50 (1H, d, J 9.6Hz), 4.62 (1H, bs), 4.45-4.30 (1H, m), 3.65-2.75 (6H, m), 1.90-1.20 (10H, m). LCMS (ES^+) RT 3.01 minutes, 566 ($\text{M}+\text{H}$) $^+$.

5 **Intermediate 46**

3-[(3-Methylphenyl)amino]-7-phenyl-2-[(2R)-2-[(tetrahydro-2H-pyran-2-yloxy)methyl]pyrrolidin-1-yl}carbonyl)thieno[2,3-b]pyridin-6(7H)-one

The title compound was prepared from Intermediate 42 (2.5g, 4.84mmol) and m-toluidine (0.62mL, 5.8mmol) following the method of Intermediate 45 to
10 give the product as an orange solid (2.27g). δH (CDCl_3) 7.76 (3H, m), 7.66 (3H, m), 7.30 (1H, m), 7.00 (3H, m), 6.54 (1H, d, J 9.7Hz), 4.68 (1H, m), 4.65 (1H, m), 3.9-3.5 (6H, m), 2.46 (3H, s), 2.10-1.50 (10H, m). LCMS (ES^+) RT 3.99 minutes, 544 ($\text{M}+\text{H}$) $^+$.

15 **Intermediate 47**

3-[(3-Chlorophenyl)amino]-7-phenyl-2-[(2R)-2-[(tetrahydro-2H-pyran-2-yloxy)methyl]pyrrolidin-1-yl}carbonyl)thieno[2,3-b]pyridin-6(7H)-one

The title compound was prepared from Intermediate 42 (1.7g, 3.3mmol) and 3-chloroaniline (0.42mL, 3.9mmol) following the method of Intermediate 45 to
20 give the product as a brown solid (900mg). δH (CDCl_3) 7.66 (3H, m), 7.35 (3H, m), 7.19 (1H, m), 6.94 (2H, m), 6.93 (1H, m), 6.42 (1H, d, J 9.67Hz), 4.53 (1H, m), 4.48 (1H, m), 3.75-3.36 (6H, m), 2.00-1.4 (10H, m). LCMS (ES^+) RT 3.90 minutes, 564 ($\text{M}+\text{H}$) $^+$.

25 **Intermediate 48**

3-[(2,4-Difluorophenyl)amino]-7-(4-methylphenyl)-2-[(2R)-2-[(tetrahydro-2H-pyran-2-yloxy)methyl]pyrrolidin-1-yl}carbonyl)thieno[2,3-b]pyridin-6(7H)-one

The title compound was prepared from Intermediate 43 (1.5g, 2.8mmol) and
30 2,4-difluoroaniline (0.35mL, 3.3mmol) following the method of Intermediate 45 to give the product as a solid (1.14g, 69%). δH (CDCl_3) 9.33 (1H, bs),

7.39-7.30 (2H, m), 7.19-7.14 (3H, m), 6.96 (1H, dd, J 14.6, 9.1Hz), 6.84 (1H, t, J 2.6Hz), 6.73 (1H, t, J 8.2Hz), 6.35 (1H, d, J 9.8Hz), 4.48-4.38 (2H, m), 3.75-3.30 (6H, m), 2.39 (3H, s), 1.97-1.5 (4H, m), 1.49-1.25 (6H, m).

5 Intermediate 49

3-[(4-Fluoro-3-methylphenyl)amino]-7-(4-methylphenyl)-2-[(2R)-2-[(tetrahydro-2H-pyran-2-yloxy)methyl]pyrrolidin-1-yl}carbonyl)thieno[2,3-b]pyridin-6(7H)-one

The title compound was prepared from Intermediate 43 (1.5g, 2.8mmol) and 4-fluoro-3-methylaniline (0.42mL, 3.3mmol) following the method of Intermediate 45 to give the product as a solid (879mg). δ H (CDCl₃) 9.41 (1H, bs), 7.48-7.38 (2H, m), 7.28-7.13 (4H, m), 6.84-6.74 (3H, m), 6.30 (1H, d, J 9.8Hz), 4.46-4.36 (2H, m), 3.71-3.25 (6H, m), 2.37 (3H, s), 2.15 (3H, s), 1.96-1.54 (6H, m), 1.45-1.40 (3H, m). LCMS (ES⁺) RT 4.21 minutes, 576 (M+H)⁺.

15

Intermediate 50

7-(4-Methylphenyl)-3-[(3-methylphenyl)amino]-2-[(2R)-2-[(tetrahydro-2H-pyran-2-yloxy)methyl]pyrrolidin-1-yl}carbonyl)thieno[2,3-b]pyridin-6(7H)-one

The title compound was prepared from Intermediate 43 (1.5g, 2.8mmol) and m-toluidine (0.37mL, 3.3mmol) following the method of Intermediate 45 to give the product as a solid (1.0g, 63%). δ H (CDCl₃) 9.29 (1H, m), 7.30-7.19 (5H, m), 7.09 (1H, t, J 8.3Hz), 6.78-6.76 (3H, m), 6.32 (1H, d, J 9.7Hz), 4.48-4.36 (2H, m), 3.76-3.32 (6H, m), 2.39 (3H, s), 2.23 (3H, s), 1.97-1.58 (6H, m), 1.54-1.42 (4H, m).

25

Intermediate 51

3-[(2,4-Difluorophenyl)amino]-7-(4-fluorophenyl)-2-[(2R)-2-[(tetrahydro-2H-pyran-2-yloxy)methyl]pyrrolidin-1-yl}carbonyl)thieno[2,3-b]pyridin-6(7H)-one

30

The title compound was prepared from Intermediate 44 (0.48g, 0.896mmol) and 2,4-difluoroaniline (0.11mL, 1.08mmol) following the method of Intermediate 45 to give the product as a yellow solid (206mg, 39%) LCMS RT 3.87 minutes, 606 (M+Na)⁺.

5

Intermediate 52

3-[(4-Fluoro-3-methylphenyl)amino]-7-(4-fluorophenyl)-2-[(2R)-2-[(tetrahydro-2H-pyran-2-yloxy)methyl]pyrrolidin-1-yl)carbonyl]thieno[2,3-b]pyridin-6(7H)-one

10 The title compound was prepared from Intermediate 44 (0.48g, 0.896mmol) and 3-methyl-4-fluoroaniline (0.135g, 1.08mmol) following the method of Intermediate 45 to give the product as a solid (90mg). δ H (CDCl₃) LCMS RT 3.94 minutes, 581 (M+H)⁺.

15 **Intermediate 53**

3-Amino-7-(2-chlorophenyl)-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carbonitrile

Acetonitrile (10mL) was added to a solution of sodium bis(trimethylsilyl)amide (100mL, 1.0M in THF, 100mmol) in THF (50mL) at -78 °C to give a thick
20 white precipitate. 2-Chlorophenyl isothiocyanate (7.72g, 45.45mmol) was added to give a brown solution. The mixture was allowed to warm to r.t. over 1h then diluted with EtOH (50mL). N,N-Dimethyluracil (6.4g, 45mmol) was added and the mixture heated at reflux for 24h. Volatiles were removed *in vacuo* and the residue dissolved in acetonitrile (100mL). Chloroacetonitrile
25 (2.85mL, 45mmol) was added and the mixture heated at 50 °C for 1h, a second charge of chloroacetonitrile (2.85mL, 45mmol) was added and heating continued for 1.5h. Some of the acetonitrile (~50mL) was removed *in vacuo* and water was added to precipitate the product. The brown solid was filtered off, washed with water (50mL) and Et₂O (50mL) and dried to give the
30 title compound as a brown solid (14.3g, quant.). δ H (DMSO-d₆) 8.10 (1H, d, J

9.7Hz), 7.75-7.73 (1H, m), 7.65-7.54 (3H, m), 7.14 (2H, br s, NH₂), 6.54 (1H, d, *J* 9.7Hz). LCMS (ES⁺) RT 2.97 minutes, 302 (M+H)⁺.

Intermediate 54

5 3-Bromo-7-(2-chlorophenyl)-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carbonitrile

Intermediate 53 (1.17g, 3.88mmol) was suspended in acetonitrile (20mL). Copper (II) bromide (953mg, 4.27mmol) was added followed by t-butyl nitrite (0.64mL, 5.43mmol). The mixture was stirred at r.t. for 3h then partitioned
10 between 2M HCl aq (100mL) and EtOAc (100mL). The organic layer was washed with 2M HCl aq (50mL), 2M NaOH aq (50mL) and water (25mL), dried (Na₂SO₄) and concentrated *in vacuo*. Purification by column chromatography (silica, 0 to 5% EtOAc in DCM) gave the title compound as a pale brown solid (980mg, 67%). ¹H (CDCl₃) 7.70 (1H, d, *J* 9.7Hz), 7.61 (1H,
15 dd, *J* 1.7, 7.7Hz), 7.52-7.44 (2H, m), 7.34 (1H, dd, *J* 1.7, 7.7Hz), 6.70 (1H, d, *J* 9.7Hz). LCMS (ES⁺) RT 3.56 minutes, 365 (M+H)⁺.

Intermediate 55

20 3-Bromo-7-(2-chlorophenyl)-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylic acid

A mixture of Intermediate 54 (1.86g, 5.0mmol) in methanol (50mL) and 2M NaOH aq (30mL) was heated at reflux for 1.5h. Volatiles were removed *in vacuo* and the residue treated with 2M HCl aq (75mL). The mixture was stirred at r.t. overnight to give a fine off-white precipitate. The solid was
25 filtered off and dried to give the title compound as an off-white solid (1.80g, 92%). ¹H (DMSO-d₆) 13.53 (1H, br s), 7.75 (1H, d, *J* 9.7Hz), 7.64-7.62 (1H, m), 7.56-7.54 (1H, m), 7.51-7.42 (2H, m), 6.52 (1H, d, *J* 9.7Hz). LCMS (ES⁺) RT 3.13 minutes, 384 (³⁵Cl⁷⁹Br) (M+H)⁺.

30 Intermediate 56

3-Bromo-7-(2-chlorophenyl)-2-((2R)-2-(hydroxymethyl)pyrrolidin-1-yl)carbonylthieno[2,3-b]pyridin-6(7H)-one

Thionyl chloride (0.66mL, 9.1mmol) was added to a suspension of Intermediate 55 (1.75g, 4.55mmol) in chloroform (50mL). The mixture was
5 heated at 50°C for 1h. A second charge of thionyl chloride (0.66mL, 9.1mmol) was added and the mixture heated at 50 °C for a further 1h then stirred at r.t. overnight and finally heated at reflux for a further 1h to give a solution. Volatiles were removed *in vacuo* and the residue dissolved in DCM (30mL). Triethylamine (0.25mL, 9.1mmol) and (R)-2-pyrrolidinemethanol
10 (0.540mL, 5.46mmol) were added and the solution stirred at r.t. for 3h. DCM (50mL) was added and the mixture washed with 2M HCl aq (100mL) and 2M NaOH aq (100mL). The organic phase was dried (Na₂SO₄) and concentrated *in vacuo* to give the title compound as a pale brown foam (2.15g, quant.). δ H (CDCl₃) 7.70 (1H, d, *J* 9.6Hz), 7.60-7.55 (1H, m), 7.48-7.32 (3H, m), 6.66
15 (1H, d, *J* 9.6Hz), 4.28-4.16 (1H, br s), 3.70-3.48 (5H, m), 2.13-2.09 (1H, m), 1.92-1.81 (1H, m), 1.79-1.59 (2H, m). LCMS (ES⁺) RT 2.91 minutes, 467 (M+H)⁺.

Intermediate 57

20 **3-Bromo-7-(2-chlorophenyl)-2-((2R)-2-((tetrahydro-2H-pyran-2-yl)oxy)methyl)pyrrolidin-1-yl)carbonylthieno[2,3-b]pyridin-6(7H)-one**
3,4-Dihydro-2H-pyran (2.0mL, 22.4mmol) and p-toluenesulfonic acid monohydrate (45mg, 5mol%) were added to a solution of Intermediate 56 (2.10g, 4.48mmol) in DCM (25mL). The mixture was stirred at r.t. for 48h
25 then diluted with DCM (50mL) and washed with a mixture of Na₂CO₃ aq (50mL) and brine (50mL). The organic phase was dried (Na₂SO₄) and concentrated *in vacuo*. Purification by column chromatography (silica, 70% EtOAc in hexane) gave the title compound as a yellow solid (2.08g, 84%). δ H (CDCl₃) 7.69 (1H, m), 7.60-7.55 (1H, m), 7.50-7.32 (3H, m), 6.65 (1H, m),
30 4.50 (1H, br m), 4.29 (1H, br m), 3.70-3.31 (6H, m), 2.06-1.80 (4H, m), 1.69-1.40 (6H, m). LCMS (ES⁺) RT 3.61 minutes, 551 (M+H)⁺.

Intermediate 58

7-(2-Chlorophenyl)-3-[(4-fluoro-3-methylphenyl)amino]-2-[(2R)-2-[(tetrahydro-2H-pyran-2-yloxy)methyl]pyrrolidin-1-yl}carbonyl)thieno[2,3-b]pyridin-6(7H)-one

- 5 From Intermediate 57 and 4-fluoro-3-methylaniline by the method of Intermediate 45. Yellow solid. δ H (CDCl₃) 9.57 (1H, br s), 7.67-7.63 (1H, m), 7.54-7.40 (3H, m), 7.25 (1H, dd, *J* 1.0, 9.8Hz), 6.95-6.85 (3H, m), 6.37 (1H, dd, *J* 1.0, 9.8Hz), 4.56-4.50 (1H, m), 4.48-4.43 (1H, m), 3.84-3.40 (6H, m), 2.24 (3H, s), 2.02-1.45 (10H, m). LCMS (ES⁺) RT 4.05 minutes, 596 (M+H)⁺.

10

Intermediate 59

7-(2-Chlorophenyl)-3-[(2,4-difluorophenyl)amino]-2-[(2R)-2-[(tetrahydro-2H-pyran-2-yloxy)methyl]pyrrolidin-1-yl}carbonyl)thieno[2,3-b]pyridin-6(7H)-one

- 15 From Intermediate 57 and 2,4-difluoroaniline by the method of Intermediate 45. Off-white solid. δ H (CDCl₃) 9.45-9.40 (1H, m), 7.64-7.61 (1H, m), 7.52-7.39 (3H, m), 7.26 (1H, d, *J* 9.8Hz), 7.07-7.01 (1H, m), 6.92-6.87 (1H, m), 6.82-6.77 (1H, m), 6.40 (1H, d, *J* 9.8Hz), 4.53-4.41 (2H, m), 3.81-3.37 (6H, m), 2.0-1.85 (3H, m), 1.82-1.67 (1H, m), 1.65-1.32 (6H, m). LCMS (ES⁺) RT 4.017 minutes, 622.1 (M+Na)⁺.

20

Intermediate 60

3-[(2,4-Difluorophenyl)amino]-7-phenylthieno[2,3-b]pyridin-6(7H)-one

- To a solution of Intermediate 28 (~4.20g) in 1,4-dioxan (10mL) was added 25 2M HCl(aq) (10mL) and the reaction mixture heated at 70°C for 1h. The reaction was diluted with water (30mL), extracted with EtOAc (3 x 30mL) and the EtOAc extracts dried (MgSO₄) and concentrated *in vacuo*. The crude residue was purified by chromatography on silica (0-5% EtOAc in DCM) to give the title compound as a pale yellow solid (2.13g). δ H (CDCl₃) 7.94 (1H, 30 d, *J* 9.4Hz), 7.64-7.53 (3H, m), 7.46 (2H, m), 7.45 (1H, m), 7.20 (1H, m), 6.99

(1H, m), 6.48 (1H, d, *J* 9.4Hz), 5.74 (1H, s). LCMS (ES⁺) RT 3.54 minutes, 354.9 (M+H)⁺.

Intermediate 61

5 **tert-Butyl (2,4-difluorophenyl)(6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridin-3-yl)carbamate**

Sodium bis(trimethylsilyl)amide (6.0mL, 1.0M in THF, 6mmol) was added to a solution of Intermediate 60 (2.0g, 5.65mmol) in THF (50mL) at 0 °C. After 30 min, di-*tert*-butyl dicarbonate (1.36g, 6.22mmol) was added and the mixture
10 stirred at r.t. for 1h. The reaction mixture was partitioned between EtOAc and brine. The aqueous phase was extracted with EtOAc (x3), the combined organic extracts washed with brine, dried (MgSO₄) and concentrated *in vacuo*. Purification by column chromatography (silica, 10% EtOAc in DCM) gave the title compound (1.2g, 47%). δH (CDCl₃) 7.45 (1H, d, *J* 9.5Hz), 7.43-
15 7.30 (3H, m), 7.22-7.19 (2H, m), 7.08-7.03 (1H, m), 6.76-6.65 (2H, m), 6.49-6.45 (2H, m), 1.26 (9H, s). LCMS (ES⁺) RT 3.79 minutes, 455 (M+H)⁺.

Intermediate 62

20 **tert-Butyl (2,4-difluorophenyl)(2-[(2*R*)-2-(hydroxymethyl)pyrrolidin-1-yl]sulfonyl)-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridin-3-yl)carbamate**

n-Butyl lithium (0.54mL of a 2.5M solution in hexanes, 1.35mmol) was added to a solution of Intermediate 61 (600mg, 1.32mmol) in THF (30mL) at -78 °C. After 20 min, sulfur dioxide gas was bubbled through the solution for 5 min.
25 The reaction mixture was allowed to warm to r.t. and solvents were removed *in vacuo*. The residue was dissolved in DCM (40mL) and *N*-chlorosuccinimide (210mg, 1.45mmol) was added. After 90 min at r.t. a solution of (*R*)-2-pyrrolidinemethanol (146mg, 1.45mmol) in DCM (5mL) was added and the mixture stirred for a further 30min. The mixture was diluted
30 with DCM and washed with brine. The organic phase was dried (MgSO₄) and concentrated *in vacuo*. Purification by column chromatography (silica, 5% to

15% EtOAc in DCM) gave the title compound (340mg, 42%). δ H (CDCl₃) 7.40-7.34 (4H, m), 7.18-7.10 (3H, m), 6.74-6.67 (1H, m), 6.65-6.58 (1H, m), 6.49 (1H, d, J 9.7Hz), 3.95 (1H, br m), 3.92-3.24 (4H br m), 1.77-1.58 (5H, br m), 1.27 (9H, s). LCMS (ES⁺) RT 3.55 minutes, 618 (M+H)⁺.

5

Intermediate 63

Sodium 3-[(2-Chlorophenyl)amino]-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate

The title compound was prepared from Intermediate 15 (1.5g, 3.52mmol) and sodium hydroxide (150mg) following the procedure of Intermediate 30 to give the title compound as a solid (1.47g). δ H (DMSO-d₆) 9.97 (1H, bs), 9.56 (1H, d, J 9.6Hz), 7.23-7.01 (2H, m), 7.26 (1H, t, J 7.0Hz), 7.34 (1H, d, J 9.5Hz), 7.47-7.13 (3H, m), 7.72-7.64 (3H, m). LCMS (ES⁺) RT 3.42 minutes, 399 (M+H)⁺.

15

Example 1

3-[(2,4-Difluorophenyl)amino]-2-[(2R)-2-(hydroxymethyl)pyrrolidin-1-yl]carbonyl-7-phenylthieno[2,3-b]pyridin-6(7H)-one

To a suspension of Intermediate 45 (7.3g, 12.9mmol) in ethanol (300mL) was added 10% HCl(aq) (40mL) and the reaction stirred at room temperature for 16h. The reaction mixture was then concentrated *in vacuo* to give an orange/brown oil. The crude product was purified by column chromatography (silica, EtOAc) followed by a second column (silica, 10% THF in DCM) to give the title compound as a light yellow solid (4.05g). δ H (CDCl₃) 9.36 (1H, bs), 7.68-7.36 (3H, m), 7.33-7.18 (2H, m), 7.14-7.06 (1H, m), 7.04-7.00 (1H, m), 6.97-6.73 (2H, m), 6.35 (1H, d, J 9.7Hz), 4.36-4.28 (1H, m), 3.74-3.47 (4H, m), 2.00-1.68 (3H, m), 1.60-1.50 (1H, m). LCMS (ES⁺) RT 3.19 minutes, 482 (M+H)⁺.

Example 2

2-[[[(2R)-2-(Hydroxymethyl)pyrrolidin-1-yl]carbonyl]-3-[(3-methylphenyl)amino]-7-phenylthieno[2,3-b]pyridin-6(7H)-one

The title compound was prepared from Intermediate 46 (2.0g, 3.68mmol) following the method of Example 1 to give the title compound as a pale yellow solid (747mg). δ H (CDCl₃) 7.77 (3H, m), 7.71 (2H, m), 7.51 (1H, d, \downarrow 9.73Hz), 7.36 (1H, m), 7.07 (3H, m), 6.58 (1H, d, \downarrow 9.75Hz), 4.57 (1H, m), 4.00-3.75 (4H, m), 2.51 (3H, s), 2.25-2.00 (3H, m), 1.81 (1H, m). LCMS (ES⁺) RT 3.18 minutes, 460 (M+H)⁺.

10

Example 3

3-[(3-Chlorophenyl)amino]-2-[[[(2R)-2-(hydroxymethyl)pyrrolidin-1-yl]carbonyl]-7-phenylthieno[2,3-b]pyridin-6(7H)-one

The title compound was prepared from intermediate 47 (0.85g, 1.5mmol) following the method of Example 1 to give the title compound as a pale yellow solid (545mg). δ H (CDCl₃) 7.60 (3H, m), 7.55 (3H, m), 7.37 (1H, m), 7.03 (2H, m), 6.95 (1H, m), 6.49 (1H, d, \downarrow 9.7Hz), 4.38 (1H, m), 3.80 (1H, m), 3.76 (1H, m), 3.62 (2H, m), 2.18 (1H, s), 1.96 (3H, m), 1.66 (1H, m). LCMS (ES⁺) RT 3.15 minutes, 480 (M+H)⁺.

20

Example 4

3-[(2,4-Difluorophenyl)amino]-2-[[[(2R)-2-(hydroxymethyl)pyrrolidin-1-yl]carbonyl]-7-(4-methylphenyl)thieno[2,3-b]pyridin-6(7H)-one

The title compound was prepared from Intermediate 48 (1.14g, 2.0mmol) following the method of Example 1 to give the title compound as a pale yellow solid (470mg, 46%). δ H (CDCl₃) 7.31-7.29 (2H, m), 7.19-7.13 (3H, m), 6.95-6.84 (1H, m), 6.83-6.80 (1H, m), 6.74 (1H, t, \downarrow 7.7Hz), 6.34 (1H, d, \downarrow 9.7Hz), 4.31-4.25 (1H, m), 3.72-3.48 (4H, m), 2.37 (3H, s), 1.96-1.73 (3H, m), 1.62-1.51 (1H, m). LCMS (ES⁺) RT 3.24 minutes, 496 (M+H)⁺.

30

Example 5

3-[(4-Fluoro-3-methylphenyl)amino]-2-[[2-(2-hydroxymethyl)pyrrolidin-1-yl]carbonyl]-7-(4-methylphenyl)thieno[2,3-b]pyridin-6(7H)-one

- 5 The title compound was prepared from Intermediate 49 (879mg, 1.52mmol) following the method of Example 1 to give the title compound as a pale yellow solid (410mg, 54%). δ H (CDCl₃) 9.35 (1H, bs), 7.30 (2H, m), 7.21-7.12 (3H, m), 6.86-6.75 (3H, m), 6.29 (1H, d, \downarrow 9.7Hz), 4.30-4.25 (2H, m), 3.72-3.70 (1H, m), 3.69-3.63 (1H, m), 3.62-3.49 (2H, m), 2.174 (3H, s), 2.170 (3H, s), 1.96-1.74 (3H, m), 1.58-1.50 (1H, m). LCMS (ES⁺) RT 3.30 minutes, 492 (M+H)⁺.

Example 6

2-[[2-(2-Hydroxymethyl)pyrrolidin-1-yl]carbonyl]-7-(4-methylphenyl)-3-[(3-methylphenyl)amino]thieno[2,3-b]pyridin-6(7H)-one

- 15 The title compound was prepared from Intermediate 50 (1.0g, 1.8mmol) following the method of Example 1 to give the title compound as a yellow solid (492mg, 56%). δ H (CDCl₃) 9.20 (1H, bs), 7.31-7.18 (5H, m), 7.09 (1H, t, \downarrow 8.0 Hz), 6.80-6.75 (3H, m), 6.30 (1H, d, \downarrow 9.6Hz), 4.29-4.19 (2H, m), 3.71-3.67 (1H, m), 3.65-3.59 (1H, m), 3.52-3.46 (2H, m), 2.37 (3H, s), 2.23 (3H, s), 1.96-1.73 (3H, m), 1.69-1.56 (1H, m). LCMS (ES⁺) RT 3.27 minutes, 474 (M+H)⁺.

Example 7

- 25 3-[(2,4-Difluorophenyl)amino]-7-(4-fluorophenyl)-2-[[2-(2-hydroxymethyl)pyrrolidin-1-yl]carbonyl]thieno[2,3-b]pyridin-6(7H)-one

- The title compound was prepared from Intermediate 51 (206mg, 0.35mmol) following the method of Example 1 to give the title compound as an off-white solid (155mg). δ H (DMSO-d₆) 8.92 (1H, s), 7.92 (1H, d, \downarrow 9.6Hz), 7.79 (2H, m), 7.66 (2H, t, \downarrow 8.6Hz), 7.51-7.46 (1H, m), 7.20-7.10 (2H, m), 6.68 (1H, d, \downarrow

9.6Hz), 4.82 (1H, m), 4.10 (1H, bs), 3.54 (1H, m), 3.44 (1H, m), 3.11 (1H, m), 1.98-1.87 (3H, m), 1.80 (1H, m). LCMS (ES⁺) RT 3.15 minutes, 500 (M+H)⁺.

Example 8

5 **3-[(4-Fluoro-3-methylphenyl)amino]-7-(4-fluorophenyl)-2-[(2R)-2-(hydroxymethyl)pyrrolidin-1-yl]carbonyl]thieno[2,3-b]pyridin-6(7H)-one**

The title compound was prepared from Intermediate 52 (90mg, 0.16mmol) following the method of Example 1 to give the title compound as a pale yellow solid (63mg). δ H (DMSO-d₆) 8.80 (1H, s), 7.81 (1H, d, J 9.6Hz), 7.66
10 (2H, m), 7.52 (2H, t, J 8.5Hz), 7.05 (1H, t, J 9.1Hz), 6.87-6.85 (1H, m), 6.82-6.78 (1H, m), 6.56 (1H, d, J 9.6Hz), 4.67 (1H, t, J 5.5Hz), 3.96 (1H, m), 3.36-3.32 (2H, m), 2.87 (1H, m), 2.20 (3H, s), 1.72-1.69 (3H, m), 1.63-1.58 (1H, m). LCMS (ES⁺) RT 3.22 minutes, 496 (M+H)⁺.

15 **Example 9**

7-(2-Chlorophenyl)-3-[(4-fluoro-3-methylphenyl)amino]-2-[(2R)-2-(hydroxymethyl)pyrrolidin-1-yl]carbonyl]thieno[2,3-b]pyridin-6(7H)-one

1M HCl aq (2mL) was added to a solution of Intermediate 58 (500mg, 0.84mmol) in EtOH (20mL) and the mixture stirred at r.t. overnight. Saturated
20 Na₂CO₃ aq (50mL) was added and the mixture extracted with EtOAc (50ml then 10mL). The combined organics were dried (Na₂SO₄) and concentrated *in vacuo*. The residual gum was treated with DCM (5mL) and then the solvent removed *in vacuo* to give the title compound as a yellow solid (400mg, 93%).
 δ H (CDCl₃) 9.47 (1H, br d, J 7.7Hz), 7.60-7.56 (1H, m), 7.49-7.33 (3H, m),
25 7.18 (1H, dd, J 0.5, 9.8Hz), 6.89-6.79 (3H, m), 6.30 (1H, dd, J 0.5, 9.8Hz), 4.33-4.31 (1H, m), 4.29 (1H, br s), 3.74-3.37 (4H, m), 2.19 (3H, d, J 1.5Hz), 1.99-1.64 (4H, m). LCMS (ES⁺) RT 3.28 minutes, 512 (M+H)⁺.

Example 10

30 **7-(2-Chlorophenyl)-3-[(2,4-difluorophenyl)amino]-2-[(2R)-2-(hydroxymethyl)pyrrolidin-1-yl]carbonyl]thieno[2,3-b]pyridin-6(7H)-one**

From Intermediate 59 by the method of Example 9. Brown solid. δ H (CDCl₃) 9.40 (1H, s), 7.65-7.62 (1H, m), 7.53-7.39 (3H, m), 7.24 (1H, d, *J* 9.9Hz), 7.10-7.04 (1H, m), 6.84-6.80 (1H, m), 6.41 (1H, d, *J* 9.8Hz), 4.40-4.34 (1H, m), 4.17-4.18 (1H, m), 3.79-3.54 (4H, m), 1.98-1.75 (3H, m), 1.55-1.50 (1H, m). LCMS (ES⁺) RT 3.247 minutes, 516 (M+H)⁺.

Example 11

3-[(2-Chlorophenyl)amino]-2-[(2R)-2-(hydroxymethyl)pyrrolidin-1-yl]carbonyl]-7-phenylthieno[2,3-b]pyridin-6(7H)-one

10 To a suspension of Intermediate 63 (1.0g, 2.4mmol) in DCM (15mL) was added EDC (0.73g, 3.7mmol, 1.5equiv.), HOBT (0.33g, 3.7mmol, 1.5equiv.) and the mixture stirred at r.t. for 15 minutes. (*R*)-2-pyrrolidinemethanol (0.25mL, 3.7mmol) was added and the reaction stirred at r.t. for 18h. The reaction was diluted with DCM (10mL), washed with water (10mL) and brine
15 (10mL), dried (MgSO₄) and concentrated *in vacuo*. The crude residue was purified by column chromatography (silica, 20% EtOAc in DCM) to give the title compound as an off-white solid (492mg). δ H (DMSO-d₆) 9.0 (1H, bs), 7.77-7.68 (7H, m), 7.38 (1H, m), 7.07 (2H, m), 6.64 (1H, d, *J* 9.6Hz), 4.78 (1H, t, *J* 5.9Hz), 4.22-4.15 (1H, m), 3.55-3.53 (2H, m), 3.46-3.39 (1H, m),
20 3.26-3.18 (1H, m), 1.99-1.77 (4H, m). LCMS (ES⁺) RT 3.28 minutes, (Cl³⁷) 482 (M+H)⁺.

General procedure for preparing amide Examples by EDC coupling

The following Examples were all prepared from the appropriate carboxylic acid intermediate and amine starting materials following the method
25 described for Example 11.

Example 12

3-[(2-Chlorophenyl)amino]-2-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]carbonyl]-7-phenylthieno[2,3-b]pyridin-6(7H)-one

30

The title compound was prepared from Intermediate 63 (500mg, 1.24mmol) and (S)-2-pyrrolidinemethanol (0.12mL, 1.86mmol) following the method of Example 11 to give the title compound as an off-white solid (40mg). δ H (CDCl₃) 7.57-7.42 (3H, m), 7.39-7.29 (4H, m), 7.14-7.05 (1H, m), 6.95-6.84 (2H, m), 6.39 (1H, d, \underline{J} 9.7Hz), 4.32-4.24 (1H, m), 3.7-3.58 (2H, m), 3.52-3.38 (2H, m), 1.97-1.49 (4H, m). LCMS (ES⁺) RT 3.27 minutes, (Cl³⁷) 482 (M+H)⁺.

Example 13

3-Anilino-2-([(2R)-2-(hydroxymethyl)pyrrolidin-1-yl]carbonyl)-7-phenylthieno[2,3-b]pyridin-6(7H)-one

The title compound was prepared from Intermediate 29 and (R)-2-pyrrolidinemethanol following the method of Example 11 to give the title compound as a pale yellow solid. δ H (CDCl₃) 7.56-7.47 (3H, m), 7.36-7.33 (2H, m), 7.27-7.19 (3H, m), 7.02-6.99 (3H, m), 6.34 (1H, d, \underline{J} 9.7Hz), 4.34-4.29 (1H, m), 3.73-3.69 (1H, m), 3.65-3.62 (1H, m), 3.57-3.48 (2H, m), 2.06-1.70 (3H, m), 1.60-1.45 (2H, m). LCMS (ES⁺) RT 3.10 minutes, 446 (M+H)⁺.

Example 14

3-Anilino-2-([(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]carbonyl)-7-phenylthieno[2,3-b]pyridin-6(7H)-one

The title compound was prepared from Intermediate 29 and (S)-2-pyrrolidinemethanol following the method of Example 11 to give the title compound as a pale yellow solid. δ H (CDCl₃) 9.31 (1H, bs), 7.55-7.46 (3H, m), 7.35-7.32 (2H, m), 7.26-7.18 (3H, m), 7.01-6.98 (3H, m), 6.33 (1H, d, \underline{J} 9.7Hz), 4.32-4.29 (1H, m), 4.14 (1H, bs), 3.73-3.64 (2H, m), 3.61-3.50 (2H, m), 1.97-1.71 (3H, m), 1.58-1.50 (1H, m). LCMS (ES⁺) RT 3.11 minutes, 446 (M+H)⁺.

Example 15

3-[(2,4-difluorophenyl)amino]-2-([(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]carbonyl)-7-phenylthieno[2,3-b]pyridin-6(7H)-one

The title compound was prepared from Intermediate 28 (1.0g, 2.58mmol) and (S)-2-pyrrolidinemethanol (390mg, 3.87mmol) following the method of Example 11 to give the title compound as a pale yellow solid (300mg). δ H (CDCl₃) 7.65-7.48 (3H, m), 7.35-7.32 (2H, m), 7.15 (1H, d, J 9.7Hz), 7.04-7.01 (1H, m), 6.99-6.72 (2H, m), 6.36 (1H, d, J 9.7Hz), 4.37-4.29 (1H, m), 3.74-3.47 (4H, m), 1.95-1.74 (3H, m), 1.61-1.53 (1H, m). LCMS (ES⁺) RT 3.18 minutes, 482 (M+H)⁺.

Example 18

10 3-Anilino-2-([(2S)-2-(methoxymethyl)pyrrolidin-1-yl]carbonyl)-7-phenylthieno[2.3-b]pyridin-6(7H)-one

The title compound was prepared from Intermediate 29 and (S)-2-(methoxymethyl)pyrrolidine following the method of Example 11 to give the title compound as a pale yellow solid. δ H (CDCl₃) 9.50 (1H, bs), 7.55-7.46 (3H, m), 7.40-7.30 (2H, m), 7.27 (1H, d, J 9.7Hz), 7.25-7.18 (2H, m), 6.99-6.95 (3H, m), 6.33 (1H, d, J 9.7Hz), 4.35-4.30 (1H, m), 3.62-3.56 (1H, m), 3.51-3.43 (2H, m), 3.41-3.30 (1H, m), 3.23 (3H, s), 1.92-1.73 (4H, m). LCMS (ES⁺) RT 3.49 minutes, 460 (M+H)⁺.

20 Example 19

3-Anilino-2-([(2R)-2-(methoxymethyl)pyrrolidin-1-yl]carbonyl)-7-phenylthieno[2.3-b]pyridin-6(7H)-one

The title compound was prepared from Intermediate 29 and (R)-2-(methoxymethyl)pyrrolidine following the method of Example 11 to give the title compound as a pale yellow solid. δ H (CDCl₃) 9.45 (1H, bs), 7.55-7.46 (3H, m), 7.40-7.30 (2H, m), 7.27 (1H, d, J 9.7Hz), 7.25-7.18 (2H, m), 6.99-6.95 (3H, m), 6.33 (1H, d, J 9.7Hz), 4.35-4.30 (1H, m), 3.62-3.56 (1H, m), 3.51-3.43 (2H, m), 3.41-3.30 (1H, m), 3.23 (3H, s), 1.92-1.73 (4H, m). LCMS (ES⁺) RT 3.49 minutes, 460 (M+H)⁺.

30

Example 20

7-(4-Chlorophenyl)-3-[(4-fluoro-3-methylphenyl)amino]-2-[(2R)-2-(hydroxymethyl)pyrrolidin-1-yl]carbonyl}thieno[2,3-b]pyridin-6(7H)-one

The title compound was prepared from Intermediate 30 (800mg, 1.87mmol) and (*R*)-2-pyrrolidinemethanol (0.28mL, 2.81mmol) following the method of

- 5 Example 11 to give the title compound as a pale yellow solid (251mg). δ H (CDCl₃) 9.43 (1H, bs), 7.51-7.48 (2H, m), 7.39-7.19 (2H, m), 7.13 (1H, d, \downarrow 9.8Hz), 6.80-6.76 (3H, m), 6.28 (1H, d, \downarrow 9.8Hz), 4.36-4.25 (2H, m), 3.75-3.50 (4H, m), 2.18 (3H, s), 1.98-1.73 (3H, m), 1.60-1.52 (1H, m). LCMS (ES⁺) RT 3.39 minutes, 512 (M+H)⁺.

10

Example 21

3-[(4-Fluoro-3-methylphenyl)amino]-2-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]carbonyl}-7-(3-methylphenyl)thieno[2,3-b]pyridin-6(7H)-one

- 15 The title compound was prepared from Intermediate 31 (1.0g, 2.4mmol) and (*S*)-2-pyrrolidinemethanol (0.36mL, 3.6mmol) following the method of Example 11 to give the title compound as a pale yellow solid (212mg). δ H (CDCl₃) 9.38 (1H, bs), 7.45-7.40 (1H, m), 7.38-7.27 (1H, m), 7.18-7.12 (3H, m), 6.87-6.76 (3H, m), 6.30 (1H, d, \downarrow 9.8Hz), 4.36-4.28 (2H, m), 3.75-3.48
20 (4H, m), 2.37 (3H, s), 2.18 (3H, s), 1.97-1.82 (3H, m), 1.70-1.59 (1H, m). LCMS (ES⁺) RT 3.34 minutes, 492 (M+H)⁺.

Example 22

2-[(2R)-2-(Hydroxymethyl)pyrrolidin-1-yl]carbonyl}-7-(3-methylphenyl)-

- 25 **3-[(3-methylphenyl)amino]thieno[2,3-b]pyridin-6(7H)-one**

The title compound was prepared from Intermediate 32 (842mg, 2.15mmol) and (*R*)-2-pyrrolidinemethanol (0.32mL, 3.23mmol) following the method of Example 11 to give the title compound as a pale yellow solid (179mg). δ H

- 30 (CDCl₃) 9.21 (1H, bs), 7.40-7.35 (1H, m), 7.27-7.24 (2H, m), 7.18-7.07 (3H, m), 6.81-6.76 (3H, m), 6.31 (1H, d, \downarrow 9.7Hz), 4.30-4.22 (2H, m), 3.70-3.46

(4H, m), 2.37 (3H, s), 2.25 (3H, s), 1.98-1.66 (3H, m), 1.58-1.47 (1H, m).
LCMS (ES⁺) RT 3.30 minutes, 474 (M+H)⁺.

Example 23

5 **3-[(4-Fluoro-3-methylphenyl)amino]-2-[(2R)-2-(hydroxymethyl)pyrrolidin-1-yl]carbonyl]-7-(3-methylphenyl)thieno[2,3-b]pyridin-6(7H)-one**

The title compound was prepared from Intermediate 31 (640mg, 1.54mmol) and (*R*)-2-pyrrolidinemethanol (0.25mL, 2.3mmol) following the method of
10 Example 11 to give the title compound as a pale yellow solid (112mg). δ H (CDCl₃) 7.49-7.35 (1H, m), 7.26 (1H, d, \downarrow 9.7Hz), 7.24-7.23 (3H, m), 6.98-6.91 (3H, m), 6.88 (1H, d, \downarrow 9.8Hz), 4.39-4.35 (1H, m), 3.83-3.56 (4H, m), 2.45 (3H, s), 2.26 (3H, s), 1.99-1.81 (3H, m), 1.68-1.60 (1H, m). LCMS (ES⁺) RT 3.34 minutes, 492 (M+H)⁺.

15

Example 24

3-[(3-Chloro-4-fluorophenyl)amino]-2-[(2R)-2-(hydroxymethyl)pyrrolidin-1-yl]carbonyl]-7-phenylthieno[2,3-b]pyridin-6(7H)-one

20 The title compound was prepared from Intermediate 33 (340mg, 0.77mmol) and (*R*)-2-pyrrolidinemethanol (0.12mL, 1.16mmol) following the method of Example 11 to give the title compound as a yellow solid (71mg). δ H (CDCl₃) 7.58-7.51 (3H, m), 7.34-7.21 (2H, m), 7.19-7.17 (1H, m), 7.05-6.98 (2H, m), 6.88-6.82 (1H, m), 6.38 (1H, d, \downarrow 9.7Hz), 4.34-4.30 (1H, m), 3.72-3.48 (4H, m), 1.99-1.53 (4H, m). LCMS (ES⁺) RT 3.21 minutes, 498 (M+H)⁺.

25

Example 25

3-[(3-Chloro-4-fluorophenyl)amino]-2-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]carbonyl]-7-phenylthieno[2,3-b]pyridin-6(7H)-one

30

The title compound was prepared from Intermediate 33 (340mg, 0.77mmol) and (S)-2-pyrrolidinemethanol (0.12mL, 1.16mmol) following the method of Example 11 to give the title compound as a yellow solid (65mg). δ H (CDCl₃) 7.66-7.59 (3H, m), 7.44-7.31 (2H, m), 7.28-7.26 (1H, m), 7.14-7.08 (2H, m),
5 6.98-6.93 (1H, m), 6.47 (1H, d, J 9.8Hz), 4.43-4.40 (1H, m), 3.81-3.57 (4H, m), 2.06-1.62 (4H, m). LCMS (ES⁺) RT 3.21 minutes, 498 (M+H)⁺.

Example 26

10 **3-[(4-Fluoro-3-methylphenyl)amino]-2-[(2R)-2-(hydroxymethyl)pyrrolidin-1-yl]carbonyl]-7-phenylthieno[2,3-b]pyridin-6(7H)-one**

(R)-2-pyrrolidinemethanol (0.398mL, 4.037mmol) was added to a solution of Intermediate 34 (1.5g, 2.69mmol) in DCM (20mL) and the mixture stirred at r.t. for 24h. The volatiles were removed *in vacuo* and the residue was
15 purified by column chromatography (silica, 1-10% THF in DCM) to produce the title compound as an orange solid (0.737g). δ H (DMSO-d₆) 8.45 (1H, s), 7.65-7.55 (4H, br m), 7.49-7.46 (2H, m), 6.98-6.93 (1H, m), 6.88-6.86 (1H, m), 6.80-6.76 (1H, m), 6.42 (1H, d, J 9.63 Hz), 4.06 (1H, m), 3.45-3.36 (3H, m), 3.21-3.17 (2H, m), 2.08 (3H, s), 1.85-1.74 (3H, m), 1.68-1.60 (1H, m).
20 LCMS (ES⁺) 478 (M+H)⁺. HPLC Chiralpak AS 80:20 Iso-Hexane/EtOH. RT 19.62 minutes.

Example 27

25 **3-[(4-Fluoro-3-methylphenyl)amino]-2-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]carbonyl]-7-phenylthieno[2,3-b]pyridin-6(7H)-one**

(S)-2-pyrrolidinemethanol (0.198mL, 2.007mmol) was added to a solution of Intermediate 34 (0.750g, 1.338mmol) in DCM (10mL) and the mixture stirred at r.t. for 24h. The volatiles were removed *in vacuo* and the residue was
30 purified by column chromatography (silica, 1-10% THF in DCM) to produce the title compound as an orange solid (0.369g). δ H (DMSO-d₆) 8.46 (1H, s),

7.65-7.55 (4H, br m), 7.49-7.46 (2H, m), 6.98-6.93 (1H, m), 6.88-6.86 (1H, m), 6.80-6.76 (1H, m), 6.42 (1H, d, J 9.63 Hz), 4.05 (1H, m), 3.46-3.35 (3H, m), 3.20-3.16 (2H, m), 2.19 (3H, s), 1.84-1.72 (3H, m), 1.68-1.60 (1H, m). LCMS (ES⁺) 478 (M+H)⁺. HPLC Chiralpak AS 80:20 Iso-Hexane/EtOH. RT 15.37 minutes.

Example 28

3-[(2,4-Difluorophenyl)amino]-2-[(3S)-3-hydroxypyrrolidin-1-yl]carbonyl]-7-phenylthieno[2,3-b]pyridin-6(7H)-one

10 (S)-3-Hydroxypyrrolidine (107mg, 1.23mmol) was added to a solution of intermediate 35 (400mg, 0.709mmol) in DCM (8mL) and the reaction stirred at room temperature for 24h. The volatiles were removed *in vacuo* and the crude residue purified by column chromatography (silica, 5-15% THF in DCM) and (silica, 20-80% EtOAc in isohexane) to give the title compound as
15 pale yellow solid (156mg). δ H (CDCl₃) 7.46-7.53 (3H, m), 7.33 (2H, m), 7.19 (1H, d, J 10.2Hz), 6.95-7.01 (1H, m), 6.82-6.87 (1H, m), 6.72-6.76 (1H, m), 6.35-6.38 (1H, m), 4.22 (1H, m), 3.64-3.69 (2H, m), 3.62 (1H, m), 3.55 (1H, m), 1.89-1.94 (2H, m). LCMS (ES⁺) RT 2.98, 468 (M+H)⁺

Example 29

3-[(2,4-Difluorophenyl)amino]-2-[(3R)-3-hydroxypyrrolidin-1-yl]carbonyl]-7-phenylthieno[2,3-b]pyridin-6(7H)-one

(R)-3-Hydroxypyrrolidine (107mg, 1.23mmol) was added to a solution of Intermediate 35 (232mg, 0.411mmol) in DCM (4mL) and the reaction stirred
25 at room temperature for 24h. The volatiles were removed *in vacuo* and the crude residue purified by column chromatography (silica, 5-15% THF in DCM) to give the title compound as a pale yellow solid (91mg). δ H (CDCl₃) 7.48 (3H, m), 7.31 (2H, m), 7.15 (1H, d, J 9.7Hz), 6.95 (1H, m), 6.82 (1H, m), 6.72 (1H, m), 6.34 (1H, d, J 9.7Hz), 4.41 (1H, m), 3.67-3.59 (3H, m), 3.53
30 (1H, m), 1.90 (2H, m). LCMS (ES⁺) RT 2.95, 468 (M+H)⁺

Example 30

3-[(4-Fluoro-3-methylphenyl)amino]-2-[(3S)-3-hydroxypyrrolidin-1-yl]carbonyl-7-phenylthieno[2,3-b]pyridin-6(7H)-one

The title compound was prepared from (S)-3-hydroxypyrrolidine (100mg, 1.10mmol) and Intermediate 34 (200mg, 0.36mmol) following the method of Example 28 to give the title compound as a pale yellow solid (55mg). δ H (CDCl₃) 7.51 (3H, m), 7.34 (2H, m), 7.19 (1H, m), 6.84 (2H, m), 6.80 (1H, m), 6.33 (1H, d, \underline{J} 9.75Hz), 4.44 (1H, m), 3.66 (4H, m), 2.18 (3H, s), 1.91 (2H, m). LCMS (ES⁺) RT 3.02 minutes, 464 (M+H)⁺

Example 31

3-[(4-Fluoro-3-methylphenyl)amino]-2-[(3R)-3-hydroxypyrrolidin-1-yl]carbonyl-7-phenylthieno[2,3-b]pyridin-6(7H)-one

The title compound was prepared from (R)-3-hydroxypyrrolidine (100mg, 1.10mmol) and Intermediate 34 (200mg, 0.36mmol) following the method of Example 28 to give the title compound as a pale yellow solid (73mg). δ H (CDCl₃) 7.65 (3H, m), 7.60 (2H, m), 7.29 (1H, m), 6.90 (3H, m), 6.48 (1H, d, \underline{J} 9.73Hz), 4.58 (1H, m), 3.80 (3H, m), 3.76 (1H, m), 2.31 (3H, s), 2.07 (2H, m). LCMS (ES⁺) RT 3.02 minutes, 464 (M+H)⁺

Example 32

3-[(2,4-Difluorophenyl)amino]-2-[(3S,4S)-3,4-dihydroxypyrrolidin-1-yl]carbonyl-7-phenylthieno[2,3-b]pyridin-6(7H)-one

The title compound was prepared from (S,S)-3,4-dihydroxypyrrolidine (110mg, 1.10mmol) and Intermediate 35 (200mg, 0.35mmol) following the method of Example 28 to give the title compound as a pale yellow solid (144mg). δ H (CDCl₃) 9.49 (1H, s), 7.51 (3H, m), 7.34 (2H, m), 7.18 (1H, m), 6.93 (1H, m), 6.84 (1H, m), 6.82 (1H, m), 6.36 (1H, d, \underline{J} 9.72Hz), 4.15 (2H, m), 3.83 (2H, m), 3.57 (2H, d, \underline{J} 12.4Hz). LCMS (ES⁺) RT 2.74 minutes, 484 (M+H)⁺.

Example 33

3-[(2,4-Difluorophenyl)amino]-2-[(3-hydroxyazetidin-1-yl)carbonyl]-7-phenylthieno[2,3-b]pyridin-6(7H)-one

The title compound was prepared from 3-hydroxyazetidine hydrochloride (110mg, 1.05mmol) and Intermediate 35 (200mg, 0.35mmol) with the addition of diisopropylethylamine (0.195mL, 1.12mmol) following the method of Example 28 to give the title compound as a white solid (64mg). δ H (CDCl₃) 9.48 (1H, s), 7.53 (3H, m), 7.32 (2H, m), 7.10 (1H, d, J 9.7Hz), 6.86 (1H, m), 6.83 (1H, m), 6.74 (1H, m), 6.33 (1H, d, J 9.8Hz), 4.58 (1H, s), 4.34 (2H, m), 3.94 (2H, m), 2.07 (1H, s). LCMS (ES⁺) RT 3.06 minutes, 454 (M+H)⁺.

Example 34

3-[(2,4-Difluorophenyl)amino]-2-[(2S)-2-(1-hydroxy-1-methylethyl)pyrrolidin-1-yl]carbonyl]-7-phenylthieno[2,3-b]pyridin-6(7H)-one

The title compound was prepared from 2-[(2S)-pyrrolidin-2-yl]propan-2-ol (140mg, 1.05mmol) and intermediate 35 (200mg, 0.35mmol) following the method of Example 28 to give the title compound as a pale yellow solid (140mg). δ H (CDCl₃) 8.95 (1H, s), 7.51 (3H, m), 7.49 (2H, m), 7.19 (1H, m), 6.87 (1H, m), 6.84 (1H, m), 6.76 (1H, m), 6.37 (1H, d, J 9.7Hz), 4.36 (1H, m), 3.90 (1H, m), 3.34 (1H, m), 1.93 (1H, m), 1.84 (1H, m), 1.67 (2H, m), 1.13 (3H, s), 1.00 (3H, s). LCMS (ES⁺) RT 3.47 minutes, 510 (M+H)⁺.

Example 35

3-[(2,4-Difluorophenyl)amino]-2-[(2R)-2-(1-hydroxy-1-methylethyl)pyrrolidin-1-yl]carbonyl]-7-phenylthieno[2,3-b]pyridin-6(7H)-one

The title compound was prepared from 2-[(2R)-pyrrolidin-2-yl]propan-2-ol hydrochloride (165mg, 1.05mmol) and Intermediate 35 (200mg, 0.35mmol) with the addition of diisopropylethylamine (0.20mL, 1.12mmol) following the method of Example 28 to give the title compound as an off-white solid

(89mg). δ H (CDCl₃) 8.96 (1H, s), 7.63 (3H, m), 7.32 (2H, m), 7.23 (1H, m), 7.01 (1H, m), 6.83 (1H, m), 6.74 (1H, m), 6.38 (1H, d, \underline{J} 9.7Hz), 5.00 (1H, s), 4.32 (1H, m), 3.90 (1H, m), 3.33 (1H, m), 2.00 (2H, m), 1.92 (2H, m), 1.15 (3H, s), 1.00 (3H, s). LCMS (ES⁺) RT 3.47 minutes, 510 (M+H)⁺.

5

Example 36

3-[(2-Cyanophenyl)amino]-2-[(2S)-2-(1-hydroxy-1-methylethyl)pyrrolidin-1-yl]carbonyl}-7-phenylthieno[2,3-b]pyridin-6(7H)-one

- 10 To a suspension of Intermediate 17 (400mg, 0.96mmol) in 2-ethoxyethanol (5mL) was added (S)-2-pyrrolidinemethanol (0.48mL, 4.81mmol) and the reaction heated at 78°C for 2 days. Solvent was removed *in vacuo* and the residue purified by column chromatography (silica, 30-80% EtOAc in isohexane) to give the title compound as a solid (123mg). δ H (CDCl₃) 9.26
- 15 (1H, bs), 7.57-7.48 (4H, m), 7.40-7.36 (3H, m), 7.26 (1H, d, \underline{J} 9.7Hz), 7.00-6.95 (2H, m), 6.44 (1H, d, \underline{J} 9.7Hz), 4.29-4.33 (1H, m), 3.68-3.61 (2H, m), 3.52-3.46 (2H, m), 1.97-1.83 (2H, m), 1.81-1.73 (1H, m), 1.60-1.53 (1H, m). LCMS (ES⁺) RT 2.98 minutes, 471 (M+H)⁺.

20 **Example 37**

3-[(2-Cyanophenyl)amino]-2-[(2R)-2-(1-hydroxy-1-methylethyl)pyrrolidin-1-yl]carbonyl}-7-phenylthieno[2,3-b]pyridin-6(7H)-one

- To a suspension of Intermediate 17 (400mg, 0.96mmol) in 2-ethoxyethanol
- 25 (5mL) was added (R)-2-pyrrolidinemethanol (0.48mL, 4.81mmol) and the reaction heated at 78°C for 2 days. Solvent was removed *in vacuo* and the residue purified by column chromatography (silica, 30-80% EtOAc in isohexane) to give the title compound as a white solid (105mg). δ H (CDCl₃) 9.25 (1H, bs), 7.57-7.48 (4H, m), 7.45-7.36 (3H, m), 7.26 (1H, d, \underline{J} 9.7Hz),
- 30 7.00-6.95 (2H, m), 6.44 (1H, d, \underline{J} 9.7Hz), 4.30 (1H, m), 3.71-3.61 (2H, m),

3.52-3.47 (2H, m), 2.00-1.87 (2H, m), 1.8-1.7 (1H, m), 1.65-1.6 (1H, m).
LCMS (ES⁺) RT 2.94 minutes, 471 (M+H)⁺.

Example 38

5 **3-Anilino-7-(cyclopropylmethyl)-2-[(2R)-2-(hydroxymethyl)pyrrolidin-1-yl]carbonyl}thieno[2,3-b]pyridin-6(7H)-one**

A mixture of Intermediate 26 (500mg, 1.4mmol) and (R)-2-pyrrolidinemethanol (2mL, 20mmol) was heated at 130°C in a sealed Schlenk tube for 6h. The reaction was cooled to room temperature and
10 partitioned between EtOAc (50mL) and water (50mL). The EtOAc layer was washed with water (2 x 20mL), dried (Na₂SO₄) and concentrated *in vacuo*. The crude residue was purified by column chromatography (silica, 20-50% EtOAc in DCM) to give the title compound as a yellow solid (405mg, 70%). δH (CDCl₃) 9.31 (1H, bs), 7.23-7.14 (3H, m), 6.99-6.94 (3H, m), 6.24
15 (1H, d, *J* 9.7Hz), 4.40-4.34 (1H, m), 4.18-4.16 (1H, m) 3.98-3.88 (3H, m), 3.76-3.58 (3H, m), 2.04-1.93 (3H, m), 1.90-1.81 (1H, m), 1.67-1.61 (1H, m), 0.62-0.58 (4H, m). LCMS (ES⁺) RT 3.12 minutes, 424 (M+H)⁺.

Example 39

20 **3-[(3-Cyanophenyl)amino]-2-[(2R)-2-(1-hydroxy-1-methylethyl)pyrrolidin-1-yl]carbonyl}-7-phenylthieno[2,3-b]pyridin-6(7H)-one**

To a suspension of Intermediate 16 (224mg) in 2-ethoxyethanol (2mL) was added (R)-2-pyrrolidinemethanol (1.0mL) and the reaction heated at 110°C
25 for 18h in a sealed tube. Solvent was removed *in vacuo* and the residue purified by column chromatography (silica, 70% EtOAc in isohexane) to give the title compound as a white solid (112mg). δH (DMSO-d₆) 9.18 (1H, s), 7.90 (1H, dd, *J* 9.6, 1.3Hz), 7.80-7.62 (5H, m), 7.51 (1H, t, *J* 7.9Hz), 7.37-7.25 (3H, m), 6.69 (1H, d, *J* 9.6Hz), 4.75 (1H, m), 4.00 (1H, m), 3.50-3.28
30 (3H, m), 2.90 (1H, m), 1.95-1.65 (4H, m). LCMS (ES⁺) RT 2.99 minutes, 471 (M+H)⁺.

Example 40

3-[(2,4-Difluorophenyl)amino]-2-[(2*R*)-2-(hydroxymethyl)pyrrolidin-1-yl]sulfonyl-7-phenylthieno[2,3-*b*]pyridin-6(7*H*)-one

- 5 A mixture of Intermediate 62 (340mg), trifluoroacetic acid (5mL) and DCM (20mL) was stirred at r.t. overnight. Solvents were removed *in vacuo* and the residue azeotroped with toluene (x3). The residue was dissolved in DCM, treated with triethylamine (10mL) and the mixture concentrated *in vacuo*. Purification by column chromatography (silica, 20% EtOAc in DCM) gave the
- 10 title compound (160mg, 23%). δ H (CDCl₃) 7.58-7.49 (3H, m), 7.36-7.31 (3H, m), 7.02 (1H, d, *J* 9.9Hz), 6.99-6.78 (3H, m), 6.38 (1H, d, *J* 9.9Hz), 3.73-3.69 (1H, m), 3.65-3.45 (2H, m), 3.35-3.28 (1H, m), 3.25-3.17 (1H, m), 2.15 (1H br m), 1.97-1.60 (4H, m). LCMS (ES⁺) RT 3.34 minutes, 518 (M+H)⁺.

Preparation of activated human p38 α for inhibitor assays.

15

Purification of human p38 α

- Human p38 α , incorporating an N-terminal (His)₆ tag, was expressed in baculovirus-infected High-Five™ cells (Invitrogen) according to the manufacturers instructions. The cells were harvested 72h post-infection and
- 20 lysed in phosphate buffered saline (PBS) containing 1% (w/v) β -octylglucoside and Complete, EDTA-free™ protease inhibitors (Roche Molecular Biochemicals). The lysate was centrifuged at 35000xg for 30min at 4oC and the supernatant applied to a NiNTA™ column (Qiagen). Bound protein was eluted by 150mM imidazole in PBS (after a wash with 15mM
- 25 imidazole in PBS) and directly applied to a HiTrap Q™ column (AP Biotech). Bound protein was eluted using a 20 column volume, 0 to 1M NaCl gradient. Fractions containing (His)₆-p38 were aliquotted and stored at -70° prior to their activation.

Preparation of GST-MKK6EE-containing lysates

E. coli (BL21 pLysS) expressing the constitutively activated form of human MKK6 fused with an N-terminal glutathione-S-transferase tag (GST-MKK6EE) were harvested by centrifugation and frozen at -70° . Cells were
5 lysed by resuspension in 1/10th the culture volume of PBS containing Complete, EDTA-free™ protease inhibitors followed by sonication on ice for 4x15 sec. Cell debris was removed by centrifugation at 35,000xg and the resultant supernatant stored in aliquots at -70° .

10 Activation of (His)6-p38

0.45mL of purified (His)6-p38 was incubated with 50μL of the GST-MKK6EE-containing lysate for 30min at 23° in the presence of 1mM β -glycerophosphate, 10mM $MgCl_2$ and 9mM ATP. The extent of activation was monitored by mass spectrometric detection of the doubly-phosphorylated
15 form of (His)6-p38, which routinely comprised greater than 90% of the final (His)6-p38 preparation. The activated (His)6-p38 was then diluted x10 in PBS and repurified using the method described above. The concentration of purified, activated (His)6-p38 was measured by UV absorbance at 280nm using $A_{280}, 0.1\% = 1.2$ and the preparation stored in aliquots at -70° prior to
20 its use in inhibitor assays.

p38 Inhibition Assays

Inhibition of phosphorylation of biotinylated myelin basic protein (MBP)

The inhibition of p38 catalysed phosphorylation of biotinylated MBP is
25 measured using a DELFIA based format. The assay was performed in a buffer comprising, 20mM HEPES (pH 7.4), 5mM $MgCl_2$ and 3mM DTT. For a typical IC50 determination, biotinylated MBP (2.5μM) was incubated at room temperature in a streptavidin-coated microtitre plate together with activated
gst-p38 (10nM) and ATP (1μM) in the presence of a range of inhibitor
30 concentrations (final concentration of DMSO is 2 percent). After fifteen minutes the reaction was terminated by the addition of EDTA (75mM). The

microtitre plate was then washed with Tris buffered saline (TBS), prior to the addition of 100 μ l of anti-phospho MBP antibody (mouse) together with europium-labeled anti-mouse IgG antibody. After one hour at room temperature the plate was again washed in TBS followed by the addition of
5 Enhancement solution (PerkinElmer Wallac). Fluorescence measurements were performed after a further fifteen minutes at room temperature.

IC50 values are determined from the plot of Log₁₀ inhibitor concentration (x-axis) versus percentage inhibition of the fluorescence generated by a control sample in the absence of inhibitor (y-axis).

10

Purification of human Peripheral Blood Mononuclear Cells

Peripheral blood mononuclear cells (PBMC) were isolated from normal healthy volunteers. Whole blood was taken by venous puncture using heparinised vacutainers (Becton Dickinson), diluted 1 in 4 in RPMI 1640
15 (Gibco, UK) and centrifuged at 400g for 35 min over a Ficoll-paque gradient (Amersham-Pharmacia Biotech, UK). Cells at the interface were removed and washed once followed by a low speed spin (250g) to remove platelets. Cells were then resuspended in DMEM containing 10% FCS, penicillin 100 units ml⁻¹, streptomycin 50 μ g ml⁻¹ and glutamine 2mM (Gibco, UK).

20

Inhibitor dilutions

Inhibitor stocks (20mM) were kept as a frozen solution (-20°C) in DMSO. Serial dilutions of inhibitors were performed in DMSO as 250-times concentrated stocks. Inhibitors were diluted 1 in 250 into tissue culture
25 media, prewarmed to 37°C and transferred to plates containing PBMC. PBMC and inhibitors were incubated together for 30 mins prior to addition of LPS. Inhibitors used in whole blood assays were prepared according to a different regime. Using the same stock solution serial dilutions of inhibitors were performed in DMSO. Inhibitors were then diluted 1 in 500 straight into

whole blood in a volume of 1µL. Inhibitor was incubated with whole blood for 30 mins prior to the addition of LPS.

LPS stimulation of PBMC

- 5 PBMC were resuspended at a density of 2×10^5 cells/well in flat bottomed 96 well tissue culture treated plates. After the addition of inhibitor cells were stimulated with an optimal dose of LPS (*E coli* strain B5:055, Sigma, at a final concentration of $1 \mu\text{g ml}^{-1}$) and incubated at 37°C in 5%CO₂/95% air for 18 hours. TNF-α levels were measured from cell free supernatants by sandwich
10 ELISA (BioSource #CHC1751).

LPS stimulation of whole blood

- Whole blood was taken by venous puncture using heparinised vacutainers (Becton Dickinson), and 500µl of blood aliquoted into each well of a 24 well
15 tissue culture treated plate. After the addition of inhibitor cells were stimulated with an optimal dose of LPS (*E coli* strain B5:055, Sigma, at a final concentration of $1 \mu\text{g ml}^{-1}$) and incubated at 37°C without CO₂ for 18 hours. TNF-α levels were measured from cell free supernatants by sandwich ELISA (BioSource #CHC1751).

20

Rat LPS induced TNF release

- Male Lewis rats (180-200g) are anaesthetised with Isoflur and injected i.v. with LPS* in a volume of 0.5ml sterile saline. After 90minutes blood is collected into EDTA tubes for preparation of plasma samples. Plasma is
25 stored at -70°C prior to assay for TNFα by commercial ELISA.

Rat CIA

- Female Lewis rats (180-200g) are anaesthetised with Isoflur and immunised i.d. at the base of the tail with 2x100µl of emulsion containing 4mg/ml bovine
30 collagen II in 0.01M acetic acid and Freund's Incomplete Adjuvant at a ratio

of 1:1. A polyarthritis develops with onset from about 13 days post sensitisation. The disease is mainly confined to the ankles and is quantified by plethysmometry. Results are expressed as change in paw volume over time.

5

In the p38 inhibitor assays described above compounds of the invention have IC_{50} values of around $1\mu M$ and below. The compounds of the invention are clearly potent inhibitors of p38 kinase, especially p38 α kinase.